

## CUMULATIVE INDEX 1992

### Volume 36

January	MEDICAL MANAGEMENT OF AIDS PATIENTS, pages 1-287
March	CIGARETTE SMOKING, pages 289-547
May	ANEMIA, pages 549-764
July	CLINICAL ALLERGY, pages 765-999
September	NEW CHALLENGES IN INTERNAL MEDICINE: A CELEBRATION OF THE 50TH ANNIVERSARY OF THE OCHSNER CLINIC, pages 1001-1274
November	TRAVEL MEDICINE, pages 1275-1535

Note: Page numbers of article titles are in **boldface** type.

- A-56268, for toxoplasmosis, in AIDS, 214  
Abdominal aorta, occlusion of, surgery for, 1166  
Abdominal pain, in AIDS, 47-48  
    in cryptosporidiosis, 217  
    in immigrants, 1470  
    in sickle cell disease, 672  
Abdominal surgery, previous, as contraindication to lung transplantation, 1213-1214  
Accidents, during travel, 1264  
    in pregnancy, 1322-1323  
Acclimatization, of high altitude travelers, 1482-1484  
Acetazolamide, for altitude illness syndromes, 1487-1488  
Acid anhydrides, and occupational asthma, 925, 928-929  
Acid hydrolases, biologic effects of, 808  
    in allergic response, 772  
Acidosis, effect in sickle cell disease, 670  
Acquired immunodeficiency syndrome.  
    See AIDS.  
Acupuncture, in smoking cessation, 463-465  
Addiction, and pharmacology of nicotine, 419-422  
    definition of, 415-419  
Addictive disorders therapy, at Mayo Nicotine Dependence Center, 496  
Adenosine, biologic effects of, 808  
Adolescents, smoking prevention in, 443-445  
Adoptive immunotherapy, medical applications of, 1029  
Adrenocorticosteroids, for pneumocystosis, 114  
*Aeromonas*, and travelers' diarrhea, 1361  
Age, effects on erythropoiesis, 620-622  
    in lung transplantation, 1213  
    in total joint replacement, 1236  
AIDS, coccidian infections in, 205-234  
    definition of, 4  
    development in HIV infection, 4-5  
    enteropathy in, 58  
    fungal infections in, CDC case definition of, 178  
    gastrointestinal manifestations in, 45-62  
    histoplasmosis in, 188-190  
    in tuberculosis, prevalence of, 126-127  
    infectious complications of, 4  
    Kaposi's sarcoma in, 235-252  
    malignant lymphoma in, 253-268  
    neuro-ophthalmic complications of, 95  
    ophthalmic problems in, 83-97  
    pneumocystosis in, 107-119  
    retinal complications of, 83-92  
    AIDS dementia complex, in late HIV infection, 67-73  
    abnormalities in, 69-70  
    immunologic markers for, 69

- AIDS dementia complex (*Continued*)  
 pathogenesis of, 71–72  
 prevalence of, 68  
 signs of, 68–69  
 spastic paraparesis with, 72  
 staging system for, 69  
 tissue damage in, 72  
 vacuolar myopathy with, 72
- AIDS-related complex, definition of, 4
- Air filtration, devices for, 948–949  
 for indoor allergen control, 947
- Air hunger, with acute anemia, 728
- Air pollutants, indoor, 936–943  
 asbestos, 938, 945  
 biological, 938–943, 945  
 carbon oxides, 937, 945  
 environmental control of, 944–948  
 formaldehyde, 937, 945  
 nitrogen oxides, 937, 945  
 nonbiological, 936–938  
 radon, 937–938, 945  
 respirable particles, 936–937, 945  
 sources of, 936–943  
 volatile organic compounds, 938, 945
- Air pollution, indoor, environmental control of, 935–952. See also *Air pollutants*.
- Air sampling, for indoor allergens, 944
- Airway(s), alterations in, cigarette smoking and, 358–359  
 epithelium of, damage to, in asthma, 908–910  
 hyperresponsiveness of, cigarette smoking and, 362–363  
 hypersensitivity of, respiratory viral illness and, 896–898  
 sinusitis and, 898–899
- maintenance of, in angioedema, 831  
 small, function of, tests of, 365–366
- Alcohol, addiction to, attributes of, 428  
 nicotine addiction vs, 430  
 and laryngeal cancer, 315  
 and oral cancer, 317
- Alcoholic liver disease, liver transplantation for, 1224
- Allergen(s), concentrations of, methods to estimate, 943–944  
 denaturation of, for indoor control, 948  
 exposure to, late-phase response to, 769–771  
 high molecular weight, and occupational asthma, 924–927  
 indoor, 938–943  
 environmental control of, 945–948  
 identification of, 944  
 low molecular weight, and occupational asthma, 925, 928–930
- Allergen immunotherapy, 977–991  
 and anaphylactic reaction, 844
- clinical efficacy of, evidence for, 979–984  
 description of, 978–979  
 dosage schedules for, 984–985  
 extracts for, 979–982  
 for allergic rhinitis, 800  
 for occupational asthma, 931  
 future prospects for, 986–987  
 indications for, 985–986  
 mechanisms of action of, 986–987  
 practical aspects of, 984–986  
 safety of, 984–986  
 side effects of, precautions against, 984–985
- Allergic disease, anti-inflammatory drugs for, 953–975  
 inflammation and, 766–768  
 mediators of, sources of, 778–782
- Allergic response, and eosinophilia, in travelers, 1423
- classification of, 860
- inflammation and, 765–787  
 inflammatory mechanisms in, 782
- Allergic rhinitis, 789–803  
 differential diagnosis of, 795–797  
 atrophic vs, 796  
 hormone-induced vs, 796  
 nasal mastocytosis vs, 796  
 nasal neoplasms vs, 797  
 nonallergic vs, 795–796  
 rhinitis medicamentosa vs, 796
- immunotherapy for, clinical efficacy of, 979–983  
 investigation of patient with, 789–791  
 laboratory tests for, 791–793  
 major syndromes of, 793–795  
 pathology of, 767–768  
 treatment of, 797–801  
 immunotherapy, 800  
 initial strategy, 801  
 nonpharmacologic, 799–800  
 pharmacologic, 797–799  
 surgical therapy, 800–801
- Alloimmunization, with blood transfusions, 738
- Alpha-methyldopa, and immune hemolytic anemia, 654
- Alpha-thalassemia, and hemolytic anemia, 663–664
- Altitude illness syndromes, 1484–1486  
 diagnosis of, 1486  
 prevention of, 1486–1488  
 treatment of, 1488–1489
- Alton Ochsner Medical Foundation, founding of, 1007
- Aluminum overload, with hemodialysis, anemia caused by, 712
- Alveolar infiltrates, in HIV infection, disorders associated with, 28

- Alveoli, alterations in, cigarette smoking and, 359
- Amebiasis, and diarrhea, in AIDS, 54
- cutaneous, in returning travelers, 1399–1400
- intestinal, in immigrants, 1469
- in returned travelers, 1434–1436
- travelers' diarrhea with, 1362
- American Cancer Society, smoking cessation program of, 454–455
- American Lung Association, smoking cessation program of, 454–455
- American Psychiatric Association, criteria for psychoactive substance dependence, 417
- Amikacin, for *Mycobacterium avium-intracellulare*, in HIV infection, 156
- Amodiaquine, for malaria prevention, in pregnant traveler, 1320
- Amphotericin B, in HIV infection, for cryptococcal infection, 186
- for esophageal candidiasis, 182
- for histoplasmosis, 189
- Amrinone, for advanced heart failure, 1073
- Analgesics, for sickle cell crisis, 673
- Anaphylactoid reactions, causes of, 845–846
- clinical findings in, 848
- differential diagnosis of, 850
- Anaphylaxis, 841–855
- acute, treatment of, 851–852
- causes of, classification of, 841–847
- clinical findings in, 847–848
- complement-mediated, 844–845
- death from, frequency of, 843
- differential diagnosis of, 849–851
- exercise-induced, 821, 847
- IgE-mediated, 841–844
- insect sting, 884–885
- immunotherapy for, 983–984
- pathogenesis of, 848–849
- prevention and prophylaxis of, 852–853
- recurrent, idiopathic, 847
- symptoms of, processes involved in, 849
- Androgens, for hereditary angioedema, 832
- for paroxysmal nocturnal hemoglobinuria, 658
- Anemia(s), aplastic, 683–697
- blood transfusions for, 734
- bone marrow transplantation vs immunosuppressive therapy for, 693–694
- clinical course of, 685
- criteria for, 684
- differential diagnosis of, 683–684
- etiology of, 684–685
- future directions in, 694
- in pregnancy, 642
- treatment of, 685–694
- blood transfusion for, 727–744
- clinical manifestations of, 727–729
- hemolytic, 649–668
- classification of, 650
- immune, 652–656
- cold-antibody, 655–656
- disorders associated with, 653
- warm-antibody, 653–655
- in elderly, 629–630
- in pregnancy, with preeclampsia/eclampsia, 642–643
- microangiopathic, 656–657
- HIV-associated, 699–709
- blood transfusions for, 736
- clinical presentation of, 700–701
- peripheral blood findings in, 700–701
- treatment of, 706
- hypoplastic/aplastic, 683–697
- blood transfusions for, 734
- in elderly, 619–630
- differential diagnosis of, 622
- etiologies of, 625
- hypoproliferative, 623–627
- management of, 622–630
- physiologic classification of, 623
- in pregnancy, 631–647
- causes of, 635–644
- impact on mother and fetus, 634
- iron deficiency, 636–639
- megaloblastic, 639–642
- prevalence of, 634–635
- in severe malaria, 1342
- iron deficiency, 553–559
- bone marrow examination in, 557
- clinical aspects of, 554–555
- etiology of, 553–554
- free erythrocyte protoporphyrin in, 558
- in elderly, 626
- in pregnancy, diagnosis of, 636–638
- effect on fetus, 636
- iron supplementation for, 638–639
- prevalence of, 636
- treatment of, 638
- iron-binding capacity in, 558
- iron therapy for, 560–562
- laboratory features of, 555–559
- peripheral blood smear in, 555–557
- serum ferritin in, 557–558
- serum iron in, 558
- serum transferrin receptors in, 558–559
- transferrin saturation in, 558
- treatment of, 560–562
- macrocytic, 581–597. See also *Macrocytosis*.
- megaloblastic, 589
- blood transfusions for, 733–734

- Anemia(s) (*Continued*)  
 in pregnancy, 639–642  
 microcytic, 549–566. See also *Anemia(s), iron deficiency*.  
 chronic disease and, 562–563  
 differential diagnosis of, 562–564  
 laboratory approach to, 563  
 sideroblastic anemia and, 564  
 thalassemia and, 563–564  
 of chronic disease, 567–579  
 blood transfusions for, 733  
 clinical features of, 567–568  
 degree of, 568  
 diagnosis of, 570–572  
 in elderly, 625  
 in HIV infection, 704  
 iron studies in, 569–570  
 laboratory features of, 568–570  
 mechanisms and pathogenesis of, 572–575  
 microcytic, 562–563  
 treatment of, 574–576  
 of renal failure, 711–725  
 etiology of, 711–714  
 pathophysiology of, 711–714  
 therapy for, 714  
 pernicious, peripheral blood smear in, 586  
 red blood cell transfusions for, perioperative, 736–737  
 refractory, 599–617. See also *Myelodysplastic syndromes*.  
 secondary, in pregnancy, prevalence of, 639  
 sickle cell. See also *Sickle cell disease*.  
 and hemolytic anemia, 665  
 in pregnancy, 644  
 sideroblastic, and ineffective erythropoiesis, in elderly, 628  
 and microcytic anemia, 564  
 signs/symptoms of, correlation with hemoglobin concentration, 731  
 spur cell, and hemolysis, 659  
 vitamin B<sub>12</sub> deficiency, in pregnancy, 642  
 Anesthetics, local, allergic reactions to, 868–869  
 anaphylactoid reaction to, 845  
 Aneurysms, surgery for, indications for, 1164  
 Angina, in chronic anemia, blood transfusion for, 730  
 in high altitude traveler, 1491  
 unstable, angiography vs angiography of, 1109  
 Angioedema, 805–840  
 acute, 807–812  
 pathophysiology of, 808–809  
 patient evaluation in, 809–811  
 treatment of, 811–812
- C1 esterase inhibitor deficiency and, 826–834  
 causes of, 810  
 chronic, 812–818  
 pathophysiology of, 813–815  
 patient evaluation in, 815–817  
 treatment of, 817–818  
 cold, 821–822  
 complement profiles with, 830  
 hereditary, anaphylaxis vs, 850  
 oropharyngeal, 827  
 pathogenesis of, 806–826  
 pathophysiology of, 829  
 physical, syndromes of, 819–823  
 therapy for, 831–834  
 Angiography, in peripheral vascular disease, 1163  
 Angioplasty, laser, for coronary revascularization, 1102–1104  
 for vascular occlusion, 1120–1121  
 Angioscopy, intracoronary, for coronary revascularization imaging, 1108–1110  
 Angiotensin-converting enzyme inhibitors, for advanced heart failure, 1074–1075  
 Animal proteins, and occupational asthma, 926  
 Anthrax, in returning travelers, 1399–1400  
 Anti-inflammatory therapy, for allergic disease, 953–975  
 for asthma, alternative, 964–970  
 comparative efficacy of, 966  
 Anti-tuberculosis drugs, in HIV infection, toxicity of, 141  
 Antianginal medication, effects of smoking on, 342  
 Antibiotics, and decreased red blood cell production, in HIV infection, 704  
 and occupational asthma, 928  
 Antibodies, deficiency of, infections with, 1137  
 evaluation of, 1140  
 in occupational asthma testing, measurement of, 922  
 Anticholinergics, for allergic rhinitis, 799  
 for asthma, 959  
 Antidepressants, for psychiatric disturbances, in HIV infection, 101–102  
 for tobacco addiction treatment, 432  
 Antigen, effect on airway reactivity, in rhinovirus respiratory infections, 903  
 Antiglobulin test, for immune hemolytic anemia, 652–653  
 Antihistamines, for acute anaphylaxis, 851  
 for allergic rhinitis, 797–798  
 for urticaria/angioedema, 823–826  
 Antihypertensive treatment, and myocardial infarction, 1047–1050

- Antilymphocyte globulin, for aplastic anemia, 686
- Antimalarials, formulations, resistance patterns, side effects and precautions for, 1333–1336
- Antimicrobial agents, for immunosuppressed patient, 1140–1141  
for travelers' diarrhea, 1366–1368  
prophylaxis with, 1363–1364
- Anti-sense oligonucleotides, medical applications of, 1029
- Antisickling agents, for sickle cell disease, 679–680
- Antithymocyte globulin, for aplastic anemia, 686
- Anxiety, in HIV infection, 100
- Anxiolytics, for psychiatric disturbances, in HIV infection, 102–103
- Aortic aneurysm, smoking-related, 335, 347
- Aortoiliac disease, angioplasty for, 1112–1113
- Aplastic crisis, in sickle cell disease, 674
- Apprehension, in anaphylaxis, 847
- Aquatic dermatitis, in returning travelers, 1408–1409
- Aquatic hazards, to pregnant traveler, 1322
- Arachidonic acid metabolism, modulators of, and anaphylaxis, 846
- Arboviral infections, and fever, in returned traveler, 1377–1378
- ARC, definition of, 4
- Arginine vasopressin system, in advanced heart failure, 1064
- Arprinocid, for toxoplasmosis, in AIDS, 214
- Arterial oxygen tension, in pulmonary disease, in HIV infection, 33
- Arteriovenous fistula, in peripheral vascular disease, 1161
- Arthropathies, with cemented total hip replacement, 1240–1241
- Arthropod bites, infestations, in returning travelers, 1396–1397
- Asbestos, as indoor air pollutant, 938, 945  
exposure to, and lung cancer, 314
- Ascariasis, and eosinophilia, in travelers, 1417–1418  
intestinal, in returned travelers, 1443–1444
- Ascaricides, for indoor allergen control, 946–947
- Ascarids, and occupational asthma, 926
- Ascites, intractable, liver transplantation for, 1220
- Aspergillosis, following heart transplantation, 1129, 1132–1133  
in HIV infection, 23
- Aspirin, allergic reactions to, 870–871
- Astemizole, for urticaria/angioedema, 824–825
- Asthma, bronchial, pathology of, 766–767  
chemical mediators of, generation of, 901–902  
cigarette smoking and, 362–363  
symptoms in, 369  
environmental tobacco smoke and, 385  
epidemiology of, 895–896  
immunotherapy for, clinical efficacy of, 799–803  
medication selection for, 957–964  
bronchodilators, 957–959  
nonbronchodilators, 959–964
- occupational, 917–934. See also *Occupational asthma*.  
progression of, staging of, 953–957  
ragweed-induced, basophils in, 905  
respiratory infections and, 895–915  
therapeutic approaches to, 911–913  
therapy for, present status of, 953  
staging of, 956–957  
virus-induced, mechanisms of, 899, 901
- Asthmatic response, late-phase, 769–770  
in viral respiratory infections, 902–906
- Atherectomy, for vascular occlusion, 1119–1120
- Atherosclerosis, and myocardial infarction, in hypertension, 1047  
effects of cigarette smoking on, 335, 337
- Atopic disease, and eosinophilia, in travelers, 1423  
inflammation in, 765–769  
mechanisms of, 771–778  
mediators in, preformed and rapidly synthesized, 771–773
- Atrial natriuretic hormones, in advanced heart failure, 1065
- Auriculopuncture, in smoking cessation, 464
- Autoimmune disease, as contraindication to lung transplantation, 1211
- Autonomic nervous system, alterations in, in asthma, 906–908
- Aversive techniques, for smoking cessation, 458
- Azithromycin, for toxoplasmosis, in AIDS, 214
- AZT, and decreased red blood cell production, in HIV infection, 704
- Bacillary angiomatosis, in HIV infection, Kaposi's sarcoma vs, 177
- Bacteremia, in HIV infection, 176–177
- Bacterial infections, and diarrhea, in AIDS, 55–57  
in HIV infection, 175–178  
pulmonary, prophylaxis against, 38

- Bactrim/Septra, for toxoplasmosis, in AIDS, 214–215
- Balanitidium coli*, intestinal, in returned travelers, 1442
- Balloon inflation, prolonged, for coronary revascularization, 1101–1102
- Barbiturates, allergic reactions to, 873
- Barotrauma, during travel, management of, 1271–1272
- Basophils, in allergic disease, 905
- BCG vaccination, for HIV infection, 146 for international travelers, 1287
- Becломethasone, structural formula for, 961
- Behavioral therapy, at Mayo Nicotine Dependence Center, 496 for psychiatric disturbances, in HIV infection, 105 in smoking cessation, 458–460
- Benzylacyclouridine, for AZT-associated anemia, in HIV infection, 706
- Beta-adrenergic agonists, for asthma, 906, 958
- Beta-adrenoreceptor blockers, for advanced heart failure, 1076–1077
- Beta-lactam antibiotics, allergic reactions to, 867 and IgE-mediated anaphylaxis, 843
- Beta-thalassemia, and hemolytic anemia, 664–665
- Bile duct, injury to, with laparoscopic cholecystectomy, 1153
- Bile salts, oral, for gallstones, 1148
- Biliary tract disease, in AIDS, 47
- Biological pollutants, as indoor allergens, 943
- Biological therapies, in multispecialty clinic, 1030–1031
- Biomedical research, in multispecialty clinic, 1028
- Bismuth subsalicylate, for travelers' diarrhea, 1366 prophylaxis with, 1363
- Bladder cancer, effect of smoking cessation on, 406 smoking as contributory cause of, 318–319
- Blastocystis hominis*, intestinal, in returned travelers, 1441–1442
- Blasts, excessive, in refractory anemia, 605
- Blister beetle lesions, in returning travelers, 1402–1403
- Blomia tropicalis*, 941
- Blood, findings in, in myelodysplastic syndromes, 603–604 loss of, and iron deficiency anemia, 553 blood transfusions for, 732–733 transfusion of, adverse effects of, 737–741 and anaphylactic reaction, 844
- choice of red blood cell products for, 732 exchange, for severe malaria, 1341 for anemia, 727–744 evaluation of need for, 729–731 immune hemolytic, 654 indications for, 731–737 of chronic disease, 576 for sickle cell crisis, 673 for sickle cell disease, 678 viscosity of, increased, with recombinant human erythropoietin, 718 volume of, total, in pregnancy, 633
- Blood gases, at altitude, 1483
- Blood pressure, increased, with recombinant human erythropoietin, 718
- Body weight, change in, effect of smoking cessation on, 411
- Bone, in sickle cell disease, 677
- Bone marrow, aspirate of, red cell precursors in, 584 aspiration and biopsy of, in macrocytic anemia, 587 cells of, growth characteristics of, in myelodysplastic syndromes, 602–603 examination of, in iron deficiency anemia, 557 failure of, in elderly, and anemia, 627 findings in, in HIV-associated anemia, 701 in myelodysplastic syndromes, 603–604 morphology of, FAB classification of, 605–606 tuberculous infection of, in HIV infection, 135
- Bone marrow transplantation, for aplastic anemia, 687–693 complications of, 689–690 conditioning regimen for, 688 cytomegalovirus screening in, 687–688 immunosuppression in, 689, 692 pretransplant management and evaluation in, 687–688 process of, 688–690 for myelodysplastic syndromes, 611
- Borrelia recurrentis* infection, fever pattern in, 1384
- Boutonneuse fever, in returning travelers, 1399
- Bradykinin, in angioedema, 829
- Breast cancer, association with smoking, 322 innovative therapies in, 1175–1176 mortality rates for, 307 prevention of, 1178–1179 tumor size and outcome in, 1175

- tumor size in, and outcome, 1175  
*Breathe-free Plan*, for smoking cessation, 455  
 Bronchial asthma, pathology of, 766-767  
 Bronchial hyperresponsiveness, inflammatory response and, 907  
 Bronchiectasis, lung transplantation for, 1207  
 Bronchiolitis, virus-induced, and asthma, 899-900  
 Bronchoconstriction, cholinergic modulation of, 908  
     with viral infection, potential mechanisms of, 912  
 Bronchodilators, for asthma, 957-959  
 Bronchopulmonary infections, in HIV infection, 175-176. See also *Pulmonary disease*.  
 Bronchoscopy, in pulmonary disease, in HIV infection, 34-36  
 Bronchospasm, cholinergic reflex, in asthma, 906  
 Brucellosis, in immigrants, 1466  
 Bruits, in peripheral vascular disease, 1161  
 Budesonide, for asthma, 960  
     structural formula for, 961
- 566C80, for toxoplasmosis, in AIDS, 214  
 C1 esterase inhibitor, characteristics of, 827  
     deficiency of, and angioedema, 826-834  
     biochemistry of, 828-829  
     pathophysiology of, 830-831  
     treatment of, 832-833  
     genomic and protein structure of, 828  
 Caffeine, addiction to, attributes of, 428  
     nicotine addiction vs, 430  
*Campylobacter*, and travelers' diarrhea, 1360-1361  
*Campylobacter jejuni*, and diarrhea, in AIDS, 56  
 Cancer, effect of smoking cessation on, 404-406  
     mortality rates for, by site, 307  
     prevention of, 1178-1180  
     smoking and, 305-331  
         incidence by site, 311-322  
         mortality from, 324  
*Candida* infection(s), following heart transplantation, 1129, 1133  
     in HIV infection, 179-182  
 Candidiasis, esophageal, in AIDS, 45, 180-181  
     in returning travelers, 1398  
 Captopril, for advanced heart failure, 1074-1075
- Carbohydrates, for altitude illness syndromes, 1487  
 Carbon monoxide, and erythropoietin inhibition, 747  
 Carbon monoxide testing, in nicotine dependence program, 501  
 Carbon oxides, as indoor air pollutants, 937, 945  
 Carcinogenesis, mechanisms of, constituents of tobacco smoke and, 308-311  
     steps in, 309  
 Carcinogens, organ-specific, in tobacco, 310  
 Cardiac arrest, smoking-related, percentage of, 335  
 Cardiac catheterization, right heart, in heart transplantation candidate, 1200  
 Cardiac disease, and travel, 1299  
 Cardiac hemolysis, and hemolytic anemia, 656  
 Cardiac output, increased, with chronic anemia, 728  
 Cardiac transplantation, 1196-1206. See also *Heart transplantation*.  
 Cardiomyopathy, heart transplantation for, 1198-1199  
 Cardiopulmonary assist, during percutaneous transluminal coronary angioplasty, 1102  
 Cardiopulmonary bypass patient, high altitude travel by, 1491  
 Cardiorespiratory disease, environmental tobacco smoke and, 384-386  
 Cardiothoracic surgery, previous, as contraindication to lung transplantation, 1213-1214  
 Cardiovascular diseases, effect of smoking cessation on, 406-407  
     in high altitude traveler, 1490-1492  
     in immigrants, 1473  
     smoking-related, 333-353  
         deaths from, 334  
         epidemiologic trends in, 333-336  
         percentages of, 335  
 Catecholamines, for advanced heart failure, 1072  
     in airway inflammation, 907  
 Cathepsin D levels, in breast cancer, 1176  
 Cats, and indoor allergens, 942  
 Cell(s), growth control mechanisms of, in myelodysplastic syndromes, 601-602  
 Cell volume, mean, during pregnancy, 637  
 Cellular biology, development of, 1027-1028  
     medical applications of, 1029  
 Cellular immune response, viral effects on, 910-911

- Cellular immunity, defects in, infections with, 1137–1140
- Central nervous system, in HIV infection, candidiasis of, 181  
cryptococcosis of, 183, 186  
disease stage and, 64  
focal lesions of, 209  
malignant lymphoma of, 256–258  
toxoplasmosis of, 208  
in sickle cell disease, 676–677
- Cephalosporins, allergic reactions to, 866–867
- Ceramics, for cementless total hip replacement, 1243
- Cercarial dermatitis, in returning travelers, 1408
- Cerebral edema, high altitude, 1485  
treatment of, 1489
- Cerebrospinal fluid, anomalies of, in early HIV infection, 66  
evaluation of, for toxoplasmosis, in AIDS, 210
- Cerebrovascular disease, as contraindication to lung transplantation, 1212  
extracranial, surgery for, indications for, 1163  
smoking-related, 345–346  
effects of cessation of, 346  
percentage of, 335
- Cervical cancer, prevention of, 1179–1180  
smoking as contributory cause of, 320–321
- Cetirizine, for urticaria/angioedema, 824–825
- Chancroid, in travelers, 1453
- Chemotherapy, for breast cancer, 1175  
for lung cancer, 1174
- Chenodiol, for gallstone therapy, 1145–1146
- Chest radiography, in pneumocystosis, 111
- Chest syndrome, acute, in sickle cell disease, 672
- Children, effect of parent's smoking on, 441–443  
environmental tobacco smoke and, 379–381  
high altitude travel by, 1493–1494  
international travel by, 1306–1311  
dermatologic problems in, 1310–1311  
immunizations for, 1307–1308  
malaria prophylaxis for, 1308–1309  
travelers' diarrhea in, 1309–1310  
internationally adopted, origins of, 1475  
screening tests for, 1477  
tropical diseases in, 1463–1480. See also under name of specific disease.
- malaria in, diagnosis and treatment of, 1345
- smoking prevention in, 442–443
- Chlamydia* infection, in travelers, 1451–1452
- Chlamydia trachomatis*, and diarrhea, in AIDS, 56–57
- Chloroguanide, for malaria, 1336  
in pregnant traveler, 1319–1320
- Chloroquine, for malaria, 1333, 1338–1339  
prevention with, in pregnant traveler, 1319  
side effects of, 1351
- Cholangiocarcinoma, liver transplantation for, 1223
- Cholangiography, endoscopic retrograde, for common duct stones, 1152
- Cholecystectomy, laparoscopic, 1149–1155  
complications with, 1154  
early clinical results of, 1153–1155  
equipment and methods for, 1151–1152  
for common duct stones, 1152–1153  
patient selection for, 1150–1151
- open, indications for, 1152
- Cholelithiasis. See *Gallstones*.
- Cholera vaccine, for international travelers, 1280–1282
- Cholestasis, with pruritus, liver transplantation for, 1220
- Cholesterol, in gallstones, 1143
- Chorioretinitis, cryptococcal, in HIV infection, 184
- Chronic disease, and anemia, 567–579.  
See also *Anemia(s), of chronic disease*.
- Chronic obstructive pulmonary disease, cigarette smoking and, mortality from, 356–357, 409  
effect of smoking cessation on, 408
- Chymopapain, allergic reactions to, 875  
testing with, for IgE-mediated anaphylaxis, 842
- Cigar smoking, and lung cancer, 312  
trends in, 297–298
- Cigarette smoking, and abdominal aortic aneurysm, 347
- and atherosclerosis, 336–342
- and cancer, inconsistent associations with, 322–323
- and cerebrovascular disease, 345–346
- and coronary heart disease, 342–345  
epidemiology of, 334
- and esophageal cancer, 317–318
- and hypertension, 347–348
- and laryngeal cancer, 315–316
- and lung cancer, 311–315
- and lung disease, 356–360
- and nicotine addiction, 415–437
- and oral cancer, 317
- and peripheral vascular disease, 346–347
- as addictive behavior, 416

- cancer deaths attributable to, 306, 324  
 cessation of. See *Smoking cessation*.  
 clinical effects of, 342–348  
 deaths attributable to, 290  
 educational status and, trends in, 293  
 effects on atherosclerosis, hematologic,  
     337, 340–341  
     metabolic, 337, 341–342  
     pathologic, 336–338  
     physiologic, 337–340  
 health consequences of, cancer, 305–331  
     cardiovascular diseases, 333–353  
     government actions aimed at, 516  
     pulmonary diseases, 355–375  
 in children and adolescents, organizations working to reduce, 447  
 in United States, trends in, 289–303  
 in workplace, direct restriction on, 389–390, 526–529  
 initiation of, trends in, 293–294, 296  
 maintenance of, role of nicotine in, 423–425  
 number smoked, trends in, 293  
 passive. See *Tobacco smoke, environmental*  
 pathophysiologic effects of, 336–342  
 prevalence of, trends in, 292  
     blacks vs whites, 300  
     educational status and, 301  
     men vs women, 299  
 prevention of, anticipatory guidance in, 440–445  
     clinician's role in, 439–449  
 public, direct restriction on, public policy on, 526–531  
 judicial restriction of, 389–392  
     constitutional claim, 390  
     discrimination claim, 390  
     due process claim, 390–391  
     First Amendment claim, 391  
     product liability claim, 392, 530–531  
     public nuisance claim, 391–392  
     state inaction claim, 391  
     workplace safety claim, 389–390  
 private restriction of, 392–393  
 state limitations on, 387  
 quit ratios for, trends in, 295  
 race and ethnic origin in, trends in, 291  
 rates of, future projections of, 298–301  
 sex and, trends in, 290–291  
 state legislation on, 386–389, 528  
 trends in, 290–298  
 type of cigarette smoked, trends in, 297
- Cimetidine, for acute anaphylaxis, 851
- Ciprofloxacin, for *Mycobacterium avium-intracellulare*, in HIV infection, 156  
 for travelers' diarrhea, 1367  
 prophylaxis with, 1363–1364
- Circulation, abnormal, and hemolytic anemia, 656–657
- Cis-platinum, for lung cancer, 1174
- Clarithromycin, for toxoplasmosis, in AIDS, 214
- Claudication, in peripheral vascular disease, 1160
- Clindamycin, for pneumocystosis, in AIDS, 112–113  
 for toxoplasmosis, in AIDS, 213–214
- Clindamycin-primaquine, for pneumocystosis prophylaxis, 114
- Clinic patients, smoking cessation among, clinician's role in, 477–494
- Clinics, role in smoking cessation, 454–456
- Clofazimine, for *Mycobacterium avium-intracellulare*, in HIV infection, 155–156
- Clonidine, for nicotine addiction treatment, 432, 507–508  
 for smoking cessation, 457
- Cloning, medical applications of, 1029
- Clostridium difficile*, and diarrhea, in AIDS, 56–57
- Clotrimazole, for esophageal candidiasis, in HIV infection, 182
- Coagulopathy, as contraindication to lung transplantation, 1212  
 disseminated intravascular, and hemolysis, 657
- Cobalamin, deficiency of, 589–594  
 etiology of, 591  
 evaluation of patients with, 591–594  
 laboratory diagnosis of, 590–591
- Cobalt, and erythropoietin production, 747
- Cocaine, addiction to, attributes of, 428
- Coccidian infections, in AIDS, 205–234
- Coccidioides immitis* infection, in HIV infection, 22, 190–191
- Coccidioidosis, intestinal, in returned travelers, 1440
- Coelenterate dermatitis, in returning travelers, 1409
- Cold agglutinin disease, and immune hemolytic anemia, 655–656
- Collagen disorders, and immune hemolytic anemia, 653–654
- Collagen vascular disease, and chronic urticaria, 816  
 as contraindication to lung transplantation, 1211
- Colon cancer, association with smoking, 322
- Colony-stimulating factors, in erythropoiesis, 745  
 innovative therapies with, 1171
- Colorectal cancer, innovative therapies in, 1177–1178  
 mortality rates for, 307  
 prevention of, 1179

- Common bile duct, stones in, treatment of, 1149, 1152-1153
- Communication, assertive, in nicotine dependence program, 510
- Community, smoking cessation programs in, 466-468
- smoking prevention programs in, physician's role in, 445-447
- Complement, activation of, in anaphylaxis, 844-845
- in chronic urticaria/angioedema, 815, 830
- measurement of, for allergic drug reactions, 862
- deficiency of, infections with, 1137
- evaluation of, 1140
- Computed tomography, for toxoplasmosis diagnosis, in AIDS, 211
- Concentration, effect of nicotine on, 422
- Conditioning, role in cigarette smoking, 418
- Congestive heart failure, in chronic anemia, blood transfusion for, 730
- patient history of, and high altitude travel, 1491
- Contact lens wear, at high altitudes, 1494
- Contrast media, allergic reactions to, 843, 845, 869-870
- Cooley's anemia, hemolysis in, 664
- Coombs test, for immune hemolytic anemia, 652
- Copper, serum, in anemia of chronic disease, 569
- Coronary angioplasty, new technologies for, 1118-1121
- atherectomy, 1119-1120
- intravascular stents, 1120
- laser angioplasty, 1120-1121
- percutaneous transluminal, for atherosclerosis, 1099-1100
- indications for, 1086-1087
- technique of, 1110-1111
- Coronary artery(ies), bypass grafting of, areas favorable to, 1088
- disease of, death from, in hypertension, 1048
- diffuse, as adverse factor in coronary revascularization, 1092-1093
- percutaneous transluminal coronary angioplasty in, 1086-1087
- dissection of, with intracoronary angiography, 1109
- lesions of, ultrasonography vs angiography of, 1107
- narrowing of, and atherosclerosis, effect of smoking on, 338
- Coronary heart disease, smoking-related, 342-345
- effects of smoking cessation on, 343-345
- epidemiology of, 334
- Coronary revascularization, adverse factors in, 1090-1093
- controversy in, 1088-1090
- indications for, future shifts in, 1093-1094
- new imaging devices for, 1105-1110
- new techniques in, 1100-1102
- new therapeutic devices for, 1102-1105
- percutaneous, 1099-1124
- Corticosteroids, for allergic rhinitis, 799
- for chronic urticaria, 817-818
- for immune hemolytic anemia, 654
- for occupational asthma, 931
- for respiratory infections/asthma, 911
- Cotton wool spots, in AIDS-related retinopathy, 84
- Craving, in nicotine addiction, definition of, 429
- Cromolyn sodium, for allergic rhinitis, 798
- for asthma, 959
- occupational, 931
- Cryptococcus neoformans* infection, in HIV infection, 22, 182-188
- diagnosis of, 185
- disseminated, 184
- pulmonary, 183, 185
- survival with, 187
- Cryptosporidiosis, and travelers' diarrhea, 1362
- in AIDS, 216-222
- clinical manifestations of, 217-218
- diagnosis of, 218-219
- diarrhea in, 51
- epidemiology of, 219-220
- historical background on, 216-217
- pathology and pathogenesis of, 219
- prevention of, 222
- treatment of, 220-222
- intestinal, in returned travelers, 1440-1441
- treatment of, 1438
- Cyclophosphamide, for aplastic anemia, with bone marrow transplantation, 692
- Cyclosporine, for aplastic anemia, 686-687
- with bone marrow transplantation, 692
- for asthma, 970
- in heart transplantation, 1126
- Cystic fibrosis, lung transplantation for, 1207, 1210
- Cysticercosis, in returning travelers, 1406-1407
- Cytogenetic abnormalities, in myelodysplastic syndromes, 601-602
- survival in, 609
- oncogenes associated with, 602
- Cytokines, in atopic disease, 773-778
- inflammation induced by, 776-778

- production of, in chronic urticaria/angioedema, 813-815
- Cytomegalovirus, in HIV infection, 23  
esophageal, 46  
nervous system, 75
- in internationally adopted children, 1476
- infection with, following heart transplantation, 1129-1131
- screening for, in bone marrow transplantation for aplastic anemia, 687
- Cytomegalovirus retinitis, in AIDS, 85-90  
diagnosis of, 86, 88  
prevalence of, 85-86  
treatment of, 88-90  
visual loss in, 86
- Cytotoxic agents, and myelodysplastic syndromes, 601, 607
- Cytotoxic therapy, in myelodysplastic syndromes, 610-611
- Dapsone, for asthma, 965-966, 970  
for pneumocystosis, 112-113  
for pneumocystosis prophylaxis, 114, 116  
for toxoplasmosis, in AIDS, 215
- ddC, for AIDS dementia complex, 71  
for HIV infection, 15
- ddl, for AIDS dementia complex, 70-71  
for HIV infection, 15
- Debilitation, as contraindication to lung transplantation, 1213
- Decongestants, for allergic rhinitis, 798
- Dehydration, in pancreas transplantation, 1230
- Dementia, in HIV infection, 68, 101
- Demyelinating neuropathies, in early HIV infection, 67
- Dengue fever, in returned traveler, 1377-1378, 1397
- Dental emergencies, during travel, management of, 1273
- Deoxygenation, in sickle cell disease, 670
- Depression, in HIV infection, 100-101
- Dermatitis, aquatic, in returning travelers, 1408-1409  
atopic, pathology of, 768
- Dermatographism, 819
- Dermatologic problems, in children, during international travel, 1310-1311  
in immigrants, 1473-1474
- Dermatology, tropical, differential diagnosis in, 1410
- Dermatophagoïdes pteronyssinus*, 940
- Development, impaired, in sickle cell disease, 671-672
- Dexamethasone, for altitude illness syndromes, 1488
- Diabetes mellitus, as adverse factor in coronary revascularization, 1090-1091  
as contraindication to heart transplantation, 1202-1203
- pancreas transplantation for, 1225  
travel precautions with, 1301-1302
- Diabetics, protamine allergy in, 874
- Dialysis, access angioplasty for, 1118  
chronic ambulatory peritoneal, anemia in, erythropoietin for, 715
- Dialyzable leukocyte extract, for cryptosporidiosis, in AIDS, 221-222
- Diarrhea, in AIDS, 49-57  
causes of, 50  
bacterial, 55-57  
protozoal, 51-55  
coccidioides, 51-52  
*Entamoeba histolytica*, 53-54  
*Giardia lamblia*, 54-55  
microsporidia, 52-53  
viral, 57  
general considerations in, 49-51  
in cryptosporidiosis, 217  
in pneumocystosis, 110  
in immigrants, 1468-1469  
travelers', 1357-1373. See also *Travelers' diarrhea*.  
with fever, in returned traveler, 1387-1388
- Diastolic function, changes in, in advanced heart failure, 1062
- Dientamoeba fragilis*, intestinal infection with, in returned travelers, 1442-1443
- Diet, in macrocytic anemia, 583
- Differentiating agents, for myelodysplastic syndromes, 611-612
- Diffusing capacity of lungs, smoking and, 366
- Digitalis, for advanced heart failure, 1071-1072
- Diisocyanates, and occupational asthma, 918, 925, 928-929
- Diloxanide furoate, for intestinal amebiasis, 1436
- Diphenhydramine, for acute anaphylaxis, 851
- Diphtheria, in immigrants, 1466-1467  
vaccine for, for international travelers, 1289-1290
- Diphyllobothrium latum*, intestinal infection with, in returned travelers, 1445
- Dipylidium caninum*, intestinal infection with, in returned travelers, treatment of, 1439
- Disseminated intravascular coagulation, and hemolytic anemia, 657  
in severe malaria, 1344
- Distress reduction, for psychiatric disturbances, in HIV infection, 104

- Diuretics, and myocardial infarction, in hypertension, 1048  
for advanced heart failure, 1070–1071
- Diving, pressure changes during, management of, 1272
- Dobutamine, for advanced heart failure, 1072–1073
- Dogs, and indoor allergens, 942
- Dopamine, for advanced heart failure, 1072–1073
- Doppler imaging, in peripheral vascular disease, 1162
- Doxycycline, for malaria, 1335, 1339  
in pregnant traveler, 1322  
prevention with, side effects of, 1351
- Drug addiction, definition of, 415–419
- Drug allergy, 857–882. See also *Drug reactions, allergic*.
- Drug dependence, criteria for, 416
- Drug reactions, allergic, and future drug requirements, 863  
determining cause of, 858–863  
complement activation measurement, 862  
history, 858  
lymphocyte blast transformation measurement, 863  
mediator release measurement, 862  
radioallergosorbent test, 861–862  
skin testing, 858–861  
specific antibody measurement, 862  
evaluation of, techniques for, 861  
IgE antibody production in, 859  
in perioperative period, 872–877  
in urticaria/angioedema, 811  
specific, 863–877  
types of, 857
- and eosinophilia, in travelers, 1422
- Drug use, and immune hemolytic anemia, 654–655  
in macrocytic anemia, 583
- Dust, as indoor allergen, 939  
collection and analysis of, 943–944
- Dust mites, as indoor allergens, 939–942  
environmental control of, 946–948
- Dyes, and occupational asthma, 928–929
- Dyserythropoiesis, in myelodysplastic syndromes, 604
- Dysgranulopoiesis, in myelodysplastic syndromes, 604
- Dysphagia, in AIDS, 45
- Dystrombopoiesis, in myelodysplastic syndromes, 604–605
- E-Z Quit, for smoking cessation, 452–453
- Eastern Europe, health care availability in, 1306–1307
- Eclampsia, hemolytic anemia with, in pregnancy, 642–643
- Economic incentives, on tobacco use, public policy on, 518, 523–526
- Ecchyma, in returning travelers, 1398
- Ectoparasites, and eosinophilia, in travelers, 1422
- Education, in multispecialty clinic, 1004–1005, 1038–1039  
on tobacco effects, public policy on, 518–522
- Eflornithine, for pneumocystosis, 112
- Ejection fraction, left ventricular, in heart transplantation candidate, 1199
- Elderly, anemia in, 619–630. See also under *Anemia(s)*.  
systolic hypertension in, antihypertensive treatment for, 1049
- Electroacupuncture, in smoking cessation, 464
- Electrolyte imbalance, with pancreas transplantation, 1230
- Elliptocytosis, hereditary, and hemolytic anemia, 660
- Emden-Meyerhof pathway, enzyme deficiencies of, and hemolytic anemia, 661
- Embryonal stem cell technology, medical applications of, 1029
- Emphysema, cigarette smoking and, 363–364  
lung transplantation for, 1207, 1210
- Enalapril, for advanced heart failure, 1074–1075
- Encephalitis, toxoplasmic, in AIDS, treatment of, 212
- Encephalopathy, portosystemic, liver transplantation for, 1220
- Endarterectomy, as adverse factor in coronary revascularization, 1092–1093
- Endocrine disorders, and eosinophilia, in travelers, 1423  
in high altitude traveler, 1493
- Endocrine manipulation, for breast cancer, 1175
- Endometrial cancer, association with smoking, 322
- Endophthalmitis, bacterial, in AIDS, 91
- Endothelial injury, and atherosclerosis, 338
- Entamoeba histolytica*, and diarrhea, in AIDS, 53–54  
intestinal, in returned travelers, 1434–1436  
treatment of, 1436, 1438
- Entamoeba polecki*, intestinal infection with, in returned travelers, 1443
- Enteric bacilli, and wheezing, 897
- Enteric fever, in immigrants, 1466  
in returned traveler, 1378

- Enteric infections, in HIV-infected traveler, 1304-1305
- Environmental control, for allergic rhinitis, 800
- of indoor pollution, 935-952
- Environmental hazards, to pregnant traveler, 1317
- Environmental tobacco smoke, 377-398
- Enzymes, and occupational asthma, 926-927
- Eosinophil(s), in atopic disease, 775-776
- in chronic urticaria/angioedema, 815
- Eosinophil chemotactic factor, biologic effects of, 808
- in allergic response, 772
- Eosinophilia, eosinophils and, 1414-1415
- in travelers, 1413-1432
  - clinical findings in, 1426-1427
  - diagnostic tests for, 1427-1428
  - diseases and disorders associated with, 1423-1424
  - drug reactions and, 1422
  - ectoparasites and, 1422
  - etiologies of, 1415-1422
  - evaluations of, 1424-1428
  - helminthic diseases and, 1425
  - history of, 1426
  - therapy for, 1428
  - with ascariasis, 1417-1418
  - with fascioliasis, 1421
  - with filariasis, 1419-1420
  - with helminthic infections, 1416-1422
  - with hookworm infection, 1418-1419
  - with intestinal flukes, 1421-1422
  - with larva migrans, 1420
  - with nematode infections, 1417-1420
  - with nonparasitic infections, 1415
  - with paragonimiasis, 1421
  - with protozoan infections, 1415-1416
  - with schistosomiasis, 1420-1421
  - with trichinosis, 1420
- Epileptics, high altitude travel by, 1492
- Epinephrine, for acute anaphylaxis, 851
- Epsilon-aminocaproic acid, for hereditary angioedema, 833
- Erythrocytes, antibodies to, in HIV-associated anemia, 705
- Erythropoiesis, effects of age on, 620-622
- impaired, in anemia of chronic disease, 572-573
  - ineffective, in elderly, management of, 627
  - regulation of, 745-755
- Erythropoietin, actions of, 748
- deficiency of, in anemia of chronic disease, 573
  - discovery of, 746
  - human, recombinant, as red blood cell transfusion alternative, 742
  - clinical effects of, 716-719
- adverse, 717-719
  - positive, 716-717
  - clinical trials of, 715-716
  - dosing schedule for, 720-721
  - for anemia of chronic disease, 576
  - for anemia of renal failure, 714
  - for HIV-associated anemia, 706
  - for regulation of erythropoiesis, 746-749
  - history of, 714-715
  - resistance to, 720
  - route of administration of, 720-721
  - in erythropoiesis, 745
  - innovative therapies with, 1172-1173
  - receptors for, 747-748
  - regulation of red cell production by, 713
  - renal production of, 746-747
  - serum, relationship to hematocrit, 1173
- Escherichia coli*, and travelers' diarrhea, 1359-1360
- Esophageal cancer, effect of smoking cessation on, 406
- smoking as cause of, 317-318
- Esophageal candidiasis, in HIV infection, 45, 180-181
- Esophagitis, granulomatous, with pulmonary tuberculosis, in HIV infection, 130
- in AIDS, 45-47
- Estrogen receptors, in breast cancer, 1176
- Ethambutol, in HIV infection, for *Mycobacterium avium-intracellulare*, 156
- for tuberculosis, 140
- Excise taxes, on tobacco use, 523-525
- Exercise testing, in heart transplantation candidate, 1199
- Extremities, chronic ischemia of, thrombolysis of, 1114-1116
- lower, angioplasty of, 1111-1114
  - occlusive disease of, surgery for, indications for, 1164
  - ulcers of, in peripheral vascular disease, 1162
- Eye(s), diseases of, in immigrants, 1474
- HIV infection of, 92
  - in sickle cell disease, 678
- FAB classification, of bone marrow morphology, 605-606
- of myelodysplastic syndromes, 608-609
- Familial Mediterranean fever, in immigrants, 1468
- Family medicine, in multispecialty clinic, 1036
- Family support, in heart transplantation candidate, 1201
- Fanconi's anemia, etiology of, 685

- Fansidar, for pneumocystosis prophylaxis, 114, 116  
for toxoplasmosis, in AIDS, 214–215
- Fascioliasis, and eosinophilia, in travelers, 1421
- Febrile nonhemolytic reaction, with blood transfusions, 740
- Femoral artery, atherectomy of, 1119–1120  
occlusion of, urokinase for, 1115
- Femoropoliteal disease, percutaneous angioplasty for, 1113
- Ferritin, in anemia of chronic disease, 574  
in iron storage, 552  
serum, during pregnancy, 637  
in iron deficiency anemia, 557–558  
level of, differential diagnosis of, 571
- Fertility, impairment of, smoking and, 410
- Fetus, effect of folate deficiency on, 639–640  
effect of iron deficiency on, 636
- Fever, in immigrants, 1464–1468  
in immunosuppressed patient, management of, 1140–1141  
in *Mycobacterium avium-intracellulare* complex disease, in HIV infection, 151  
in pneumocystosis, 110  
in returned traveler, 1375–1392  
concomitant symptom complexes in, 1387–1390  
diarrhea, 1387–1388  
hepatic lesions, 1389–1390  
neurologic symptoms, 1390  
respiratory infection, 1388–1389  
diagnosis of, clues to, 1379–1383  
lymphadenopathy, 1386–1387  
physical findings in, 1383–1387  
rash, 1385–1386  
splenomegaly, 1385–1386  
temperature characteristics in, 1383–1385  
exposures and, 1379–1381  
immunization and prophylaxis history in, 1383  
incubation period of, 1381–1382  
length of stay and, 1379  
living conditions and, 1379  
patterns of, 1383–1385  
rash with, 1385–1386  
risk of, 1375–1376  
travel history in, 1379  
tropical, 1376–1378
- Filariasis, and eosinophilia, in travelers, 1419–1420  
in immigrants, 1468
- Fire ant stings, allergic reaction to, 891
- Fish allergies, protamine allergy with, 874
- Five-day Plan, for smoking cessation, 455
- Flow cytometry, in breast cancer, 1176
- Flu-like symptoms, with recombinant human erythropoietin, 718
- Fluconazole, in HIV infection, for  
cryptococcal infection, 187  
for oral candidiasis, 182
- Flucytosine, for cryptococcal infection, in  
HIV infection, 186
- Fluids, for altitude illness syndromes, 1487
- Flunisolide, structural formula for, 961
- 5-Fluorouracil, for colorectal cancer, 1177
- Flushing, in anaphylaxis, 847
- Fluxes, and occupational asthma, 929–930
- Flying, emergencies and hazards during, 1299–1300  
pressure changes during, management of, 1271–1272
- prolonged, pulmonary emboli after, 1300
- pulmonary symptoms during, prediction of, 1296–1299
- Folate, deficiency of, 594–595  
and anemia, in elderly, 627  
in pregnancy, and megaloblastic anemia, diagnosis of, 641  
changes in red cell concentration of, 640  
effect on fetus, 639–640  
predisposing factors to, 640  
prevalence of, 639  
with hemodialysis, 712
- in macrocytosis, 587
- in normal pregnancy, 639
- Folic acid, for paroxysmal nocturnal hemoglobinuria, 658  
synthesis of, inhibitors of, for toxoplasmosis, in AIDS, 214–215
- Food additives, and chronic urticaria/angioedema, 816
- Food allergy, and anaphylactic reaction, 844  
and urticaria/angioedema, 811
- Forced expiratory volume, cigarette smoking and, cross-sectional studies of, 364–365  
population-based studies of, 366–367  
decline in, cigarette smoking and, 361, 409–410
- Forced vital capacity, cigarette smoking and, cross-sectional studies of, 364–365
- Formaldehyde, as indoor air pollutant, 937, 945
- Foscarnet, for cytomegalovirus retinitis, in AIDS, 90
- Free erythrocyte protoporphyrin, in iron deficiency anemia, 558
- Free will, nicotine addiction vs, 425–427
- Freedom from Smoking*, for smoking cessation, 453

- Freezing, for indoor allergen control, 947  
*FreshStart*, for smoking cessation, 454–455  
 Fungal infections, in HIV infection, 178–192  
     epidemiology of, 179  
     pulmonary, prophylaxis against, 38–39  
 Fungicides, for indoor allergen control, 947  
 Furry pets, 948  
     and indoor allergens, 942
- Gallium-67 lung scanning, in pulmonary disease, in HIV infection, 32  
 Gallstones, 1143–1157  
     extracorporeal shockwave lithotripsy for, 1147–1148  
     in common bile duct, treatment of, 1149, 1152–1153  
     pathophysiology of, 1144  
     pigmented, 1144  
     risk factors for, 1144–1145  
     therapy for, 1145–1148  
         chenodiol, 1145–1146  
         dissolution, 1145–1147  
         methyl-tertiary-butyl ether, 1146–1147  
         surgical, 1149–1155  
         ursodiol, 1145–1146  
 Gamma globulin, intravenous, for asthma, 970  
 Ganciclovir, for cytomegalovirus retinitis, in AIDS, 88  
 Gastrectomy, and iron deficiency anemia, 553  
 Gastrointestinal disease, as contraindication to heart transplantation, 1204  
 Gastrointestinal disorders, and eosinophilia, in travelers, 1423  
     in immigrants, 1468–1470  
 Gastrointestinal manifestations, in AIDS, 45–62  
     bleeding, 48–49  
     obstruction and perforation, 48  
 Gene transfer, medical applications of, 1029  
 Genital ulceration, in travelers, causes of, 1452–1453  
 Genitourinary system, in sickle cell disease, 675–676  
*Giardia lamblia*, and diarrhea, in AIDS, 54–55  
     intestinal infection with, in immigrants, 1469  
     in returned travelers, 1437, 1440  
     treatment of, 1439–1440  
 Giardiasis, travelers' diarrhea with, 1361–1362  
 Glucocorticoids, for asthma, 959–964  
     inadequate response to, 963  
     inhaled, 960–962  
     pharmacokinetics and pharmacodynamics of, 962–963  
     recommended doses for, 962  
     systemic, 960  
     structural formula for, 961  
 Glucose-6-phosphate dehydrogenase deficiency, and hemolytic anemia, 662–663  
 GM-CSF, for regulation of erythropoiesis, 750  
 Gnathostomiasis, in returning travelers, 1402, 1406  
 Gold, for asthma, 965–966, 969  
 Gonorrhea, in travelers, 1449–1451  
 Graduate education, in multispecialty group, 1021–1024  
 Graft rejection, with bone marrow transplantation, for aplastic anemia, 691–692  
 Graft-versus-host disease, with blood transfusions, 740–741  
     with bone marrow transplantation, for aplastic anemia, 690–691  
 Gram-negative sepsis, in severe malaria, 1343  
 Granulocyte colony stimulating factor (G-CSF), innovative therapies with, 1171  
 Granulocyte-macrophage colony-stimulating factor (GM-CSF), for regulation of erythropoiesis, 750  
     in mycobacterial disease, in HIV infection, 157  
     innovative therapies with, 1171  
 Granulomatous reaction, with cemented total hip replacement, 1241  
 Grass pollen, seasonal exposure to, effect on mast cell numbers, 767  
 Great American Smokeout, for smoking cessation, 466  
 Grief and loss, in nicotine dependence program, 510  
 Group therapy, in smoking cessation, 454–456  
 Growth, impaired, in sickle cell disease, 671–672  
 Growth factors, for cementless total hip replacement, 1243  
     for myelodysplastic syndromes, 612–613  
 Growth hormone, human, for regulation of erythropoiesis, 751–752  
 Gum, nicotine. See *Nicotine polacrilex (Nicorette)*.  
 Gynecologic concerns, in high altitude traveler, 1493–1494  
*Haemophilus influenzae*, and wheezing, 897

- Haemophilus influenzae* (Continued)  
 vaccine for, for international travelers, 1289, 1292
- Halofantrine, for malaria, 1336, 1339  
 in pregnant traveler, 1321–1322
- Ham's test, for paroxysmal nocturnal hemoglobinuria, 658
- Haptens, and IgE-mediated anaphylaxis, 843
- Head lice, in returning travelers, 1397
- Headache, in early HIV infection, 65–66
- Health benefits, of smoking cessation, 399–414
- Health care, in Eastern Europe, availability of, 1306–1307  
 in multispecialty clinic, delivery of, innovation in, 1031–1032  
 strategy formulation for, 1035–1036  
 in multispecialty group, adaptability of, 1023–1024
- Health considerations, for travelers, 1295–1312
- Health insurance, for travel, 1267
- Health maintenance organization, in multispecialty clinic, 1036
- Healthcare worker, HIV infection and, 269–280
- Heart disease, end-stage, heart transplantation for, 1198–1199  
 prognostic factors in, 1069  
 ischemic, environmental tobacco smoke and, 385
- Heart failure, advanced, 1057–1082  
 biochemical changes in, 1063  
 cardiac catheterization in, 1068  
 cardiac transplantation for, 1077  
 causes of death in, 1067  
 clinical findings in, 1058, 1066  
 compensatory mechanisms in, 1061  
 disease processes causing, 1058  
 echocardiography in, 1068  
 electrocardiography in, 1067  
 endomyocardial biopsy in, 1068  
 epidemiology of, 1059  
 functional capacity in, 1068–1069  
 mechanical changes in, 1062  
 neuroendocrine function in, 1063–1064  
 neurohumoral factors in, 1064–1065  
 pathophysiology of, 1059–1064  
 patient evaluation in, 1065–1069  
 peripheral factors in, 1064–1065  
 radionuclide studies in, 1068  
 therapy of, 1069–1077  
 nonpharmacologic, 1070  
 pharmacologic, 1070–1077
- Heart rate, smoking and, 339
- Heart transplantation, contraindications to, 1201–1205  
 for advanced heart failure, 1077
- immunosuppression for, 1127  
 improved survival in, 1126  
 indications for, 1197–1201  
 infections in, 1125–1134  
 types of, 1128–1129  
 methods of, 1126–1127  
 patient selection for, 1196–1206  
 clinical evaluation, 1196–1197  
 functional status, 1199–1201  
 results in, 1127–1131
- Heart-lung transplantation, indications for, 1208–1209
- Heat, for indoor allergen control, 947
- Helminthic infection, and eosinophilia, in travelers, 1416–1422, 1425
- intestinal, in returned travelers, 1443–1445
- Helping Smokers Quit Kit*, for smoking cessation, 453
- HELPP syndrome, in pregnancy, 642–643
- Hematocrit, during pregnancy, 633–634  
 relationship to serum erythropoietin, 1173  
 with recombinant human erythropoietin therapy, 716–717
- Hematologic diseases, in high altitude traveler, 1493  
 in immigrants, 1472
- Hematologic system, effects of smoking on, 340–341
- Hematology, innovative therapies in, 1169–1184
- Hematopoiesis, growth factors for, innovative therapies with, 1169–1173  
 schema of, 1170
- Hematopoietic cancer, smoking as contributory cause of, 321–322
- Hemodialysis, folate deficiency with, 712
- Hemoglobin(s), composition of, manipulation of, for sickle cell disease, 679–680  
 concentration of, correlation with signs/symptoms of anemia, 731  
 in sickle cell disease, 669–670  
 during pregnancy, 634, 637  
 production of, abnormalities of in pregnancy, 643–644  
 unstable, and hemolytic anemia, 665–666
- Hemoglobin iron, decreased utilization of, in anemia of chronic disease, 573
- Hemoglobinopathies, and hemolytic anemia, 665–666
- Hemoglobinuria, cold, paroxysmal, 656  
 in intravascular hemolysis, 651  
 march, and hemolysis, 657  
 nocturnal, paroxysmal, 658
- Hemolysis, clinical evaluation of, 650–651  
 definition of, 649  
 extravascular, 651–652

- intramedullary, 623
- intravascular, 651
- mechanisms of, 649
- toxic effect on red cells and, 657–658
- Hemolytic disorders, acquired, 652–659
  - hereditary, 659–666
  - immune, blood transfusions for, 734–735
    - in HIV-associated anemia, 705
  - Hemolytic reaction, delayed, with blood transfusions, 739–740
  - Hemolytic-uremic syndrome, and hemolytic anemia, 657
  - Hemopexin, in intravascular hemolysis, 651
  - Hemosiderin, in iron storage, 552
  - Hemosiderosis, with blood transfusions, 738
  - Heparin, biologic effects of, 808
  - Hepatic disease, as contraindication to heart transplantation, 1204
    - as contraindication to lung transplantation, 1211
  - Hepatic diseases, in immigrants, 1470–1471
  - Hepatic lesions, with fever, in returned traveler, 1389–1390
  - Hepatitis, in immigrants, 1470–1471
    - in travelers, 1453–1454
    - infectious, and fever, in returned traveler, 1378
    - viral, with blood transfusions, 739
  - Hepatitis B, infection with, as contraindication to liver transplantation, 1223
    - in internationally adopted children, 1475–1476
    - vaccine for, for international travelers, 1282–1283, 1289
  - Hepatobiliary system, in sickle cell disease, 674
  - Hepatocellular carcinoma, liver transplantation for, 1223
  - Heroin, addiction to, attributes of, 428
    - nicotine addiction vs., 430
  - Herpes infection, following heart transplantation, 1131
  - Herpes simplex virus, esophageal, in AIDS, 46
  - HETE, in allergic response, 773
  - Heterotopic ossification, with total hip replacement, 1239
  - Hexose-monophosphate shunt, enzyme deficiencies of, and hemolytic anemia, 661–663
  - High altitude, and pregnant traveler, 1322
    - cerebral edema at, 1485, 1489
    - pulmonary edema at, 1485, 1488–1489
    - retinopathy at, 1486, 1489
  - High altitude medicine, 1481–1497
  - Hip, total joint replacement of, 1239–1243
    - cemented, 1240–1242
    - clinical outcome with, 1240–1241
    - loosening of, 1241–1242
    - revision arthroplasty with, 1242
    - stress shielding of, 1242
    - cementless, 1242–1243
    - complications of, 1239–1240
    - definition of, 1239
  - Histamine, basophil release of, in allergic drug reactions, 862
    - biologic effects of, 808
    - effect on airway reactivity, in rhinovirus respiratory infections, 903
    - in allergic response, 772
    - in virus-induced asthma, 901
  - Histoplasma capsulatum* infection, in HIV infection, 22–23, 188–190
  - Histoplasmosis, in HIV-infected traveler, 1306
  - HIV-1, genes and gene products of, 6
  - HIV infection, AIDS development in, 4–5
    - and healthcare worker, 269–280
    - anemia associated with, 699–709. See also under Anemia(s).
    - diagnosis of, 1–18, 271–272
    - epidemiology of, 1–4
    - healthcare worker risk of, 272–273
    - illness prevention in, strategies for, 12–13
    - in traveler, 1454–1455
    - precautions with, 1303–1306
    - restrictions with, 1455
  - in tuberculosis patients, prevalence of, 126–127
  - initial evaluation of, 10–12
    - management of, 1–18
    - medical, 9, 11
  - maternal-infant transmission of, 3
  - mycobacterial disease in, 121–171
  - nervous system abnormalities in, 63–81
    - of eye, 92
  - opportunistic infections in, 173–203
  - parenteral transmission of, 270
  - patient risk of, 275–276
  - pneumocystosis in, 107–119
    - postexposure prophylaxis against, 274–275
  - progression to AIDS, 2
  - psychiatric disturbances in, 99–106
  - pulmonary disease in, 19–44
    - risk from transfusion, 3
    - serology of, indeterminate, 7–9
    - testing policies for, 9
    - treatment of, 13–14
  - tuberculin skin testing in, 143–144
  - tuberculosis and, 121–147
    - spectrum of, 132
  - universal precautions against, 273–274
  - virology of, 5–6
  - with blood transfusions, 739

- HIV-related disease, as contraindication to lung transplantation, 1212
- Hodgkin's disease, AIDS-associated, 263–264
- Hookworm, and eosinophilia, in travelers, 1418–1419
- in immigrants, 1469–1470
  - in returned travelers, 1444
- Hospitalization time, with laparoscopic cholecystectomy, 1153
- Host defense(s), abnormalities of, in HIV infection, 174
- against infection, normal mechanisms of, 1135–1136
- H,R antagonists, for chronic urticaria, 817
- HTLV-1 infection, in travelers, 1455
- Humidity control, for indoor allergen control, 947
- Humoral immunity, evaluation of, 1140
- Hydralazine, for advanced heart failure, 1075–1076
- Hydration, for sickle cell crisis, 672–673
- Hydrocortisone, structural formula for, 961
- Hydroxychloroquine, for asthma, 965–966, 969
- Hydroxynaphthoquinolones, for toxoplasmosis, in AIDS, 214
- Hymenolepis nana*, intestinal infection with, in returned travelers, 1445
- Hymenoptera sting, allergy to, 883–894
- and anaphylactic reaction, 843–844
- Hypercholesterolemia, and myocardial infarction, in hypertension, 1048
- Hyperkalemia, in pancreas transplantation, 1230
- with recombinant human erythropoietin, 718
- Hypersensitivity, immediate, concept of, inconsistencies with, 768–769
- in drug allergy, skin testing for, 858–861
- Hypertension, 1043–1056
- essential, end-stage renal disease and, 1050–1052
  - in high altitude travelers, 1491
  - left ventricular hypertrophy in, 1044–1046
  - pulmonary, in high altitude travelers, 1482
  - renovascular, renal artery angioplasty for, 1117
  - smoking-related, 335, 347–348
  - with recombinant human erythropoietin, 717
- Hypertransfusion therapy, for sickle cell disease, indications for, 678
- Hyperventilation, in high altitude travelers, 1482
- with chronic anemia, 729
- Hypnotherapy, in smoking cessation, 462–463
- Hypoglycemia, in severe malaria, 1342
- Hypotension, in severe malaria, 1343–1344
- with acute anemia, 728
- Hypoxia, and erythropoietin production, 747
- during flying, 1300–1301
  - in high altitude travelers, 1482, 1484
- I Quit Kit*, for smoking cessation, 452–453
- IgE, anaphylaxis mediated by, 841–844
- antibodies to, production of, 859
  - autoantibodies to, in chronic urticaria/angioedema, 815
  - regulation of, in atopic disease, 774–775
  - venom-specific, in insect sting allergy, 886
- IGF-1, for regulation of erythropoiesis, 751–752
- IgG antibodies, measurement of, for allergic drug reactions, 862
- virus-specific, production of, relationship to airway obstruction, 899–901
- IgM antibodies, measurement of, for allergic drug reactions, 862
- Iliac stenosis, angioplasty for, 1112
- Illness, during travel, 1264–1266
- Imidazole, for oral candidiasis, in HIV infection, 181
- Immediate hypersensitivity, concept of, inconsistencies with, 768–769
- in drug allergy, skin testing for, 858–861
- Immigrants, tropical diseases in, 1463–1480. See also under name of specific disease.
- Immune globulin(s), for humoral immunodeficiency, 1136–1137
- for international travelers, 1280, 1283–1284
- Immune system, compromise of, and nervous system abnormalities, 63–64
- evaluation of, 1140–1141
  - function of, alterations in, cigarette smoking and, 359–360
  - modulators of, for toxoplasmosis, in AIDS, 215
  - suppression of, at high altitudes, 1494
- Immunization(s), for HIV-infected traveler, 1303–1304
- for international travel, 1277–1294
  - dosing schedules for, 1280
  - for children, 1307–1308
  - recommendations for, 1277–1278
  - vaccines for, recommended, 1282–1288

- required, 1278–1282
- routine, 1288–1293
- selection of, 1278
- for pregnant traveler, 1314–1316
- for travel, 1261–1263
- Immunodeficiency, infection in, 1135–1142**
- Immunomodulator therapy, for asthma, 970–971**
- Immunosuppression, for aplastic anemia, 686–687**
  - for immune hemolytic anemia, 654
  - in heart transplantation, 1126
  - in pancreas transplantation, risks of, 1230
- Immunotherapy, allergen, 977–991.** See also *Allergen immunotherapy*.
  - In Control*, for smoking cessation, 453
  - Indoor air pollution, environmental control of, 935–952. See also *Air pollution*.
  - Infants, effect of parent's smoking on, 441–442
  - environmental tobacco smoke and, 379–380
  - international travel with, 1306–1311. See also under *Children*.
- Infection(s), and anemia of chronic disease, 568**
  - host defense against, normal mechanisms of, 1135–1136
  - in heart transplantation, 1125–1134
  - in immunocompromised host, 1135–1142
  - susceptibility to, in sickle cell disease, 671
  - with bone marrow transplantation, for aplastic anemia, 690
  - with cellular immunity defects, 1137–1138
  - with humoral immunodeficiency, 1136–1137
  - with phagocytic system defects, 1139–1141
  - with total hip replacement, 1240
  - with total knee replacement, 1245
- Infectious diseases, tropical, incubation periods of, 1382**
- Inflammation, and allergic response, 765–787**
  - and anemia, in elderly, 625
  - and anemia of chronic disease, 568
  - cytokine induction of, 776–778
  - mediators of, in allergic disease, sources of, 778–782
  - with allergen exposure, 770
- Influenza, cigarette smoking and, 370–371**
  - mortality from, effect of smoking cessation on, 408
- prophylaxis against, in HIV infection, 38**
- vaccination against, for international travelers, 1289, 1292**
- for respiratory infections/asthma, 911**
- Inhalant allergens, and chronic urticaria, 816**
  - immunotherapy against, clinical efficacy of, 979–983
  - in urticaria/angioedema, 811
- Innovative therapies, in multispecialty clinics, 1025–1033**
- Inotropic agents, for advanced heart failure, 1071–1074**
- Insect(s), and occupational asthma, 926**
  - as indoor allergens, 942–943
  - environmental control of, 948
- Insect stings, allergy to, 883–894**
  - causative agents in, 883–884
  - diagnosis of, 886–887
  - immunopathogenesis of, 885
  - natural history of, 885–886
  - therapy for, 887–891
  - avoidance, 887
  - medical, 887–888
  - venom immunotherapy, 888–891
  - anaphylaxis with, immunotherapy for, 983–984
  - clinical reactions to, 884–885
  - in pregnant traveler, 1318–1319
  - in returning travelers, 1395–1397
  - in urticaria/angioedema, 811
- Insecticides, and occupational asthma, 929**
- Insulin, allergic reactions to, 871–872**
  - dosage adjustments of, during travel, 1302
- Insulin-like growth factor 1, for regulation of erythropoiesis, 751–752**
- Insurance premium differentials, tobacco use and, 525**
- Interferon, for mycobacterial disease, in HIV infection, 157**
  - in IgE regulation, 774
- Interferon gamma, for toxoplasmosis, in AIDS, 215**
- Interleukin(s), and inflammation, 777**
  - in eosinophilia, 775
  - in IgE regulation, 774
- Interleukin-1, in anemia of chronic disease, 573–574**
- Interleukin-2, for mycobacterial disease, in HIV infection, 157**
  - for regulation of erythropoiesis, 752
  - for toxoplasmosis, in AIDS, 215
- Interleukin-3, for regulation of erythropoiesis, 749–750**
  - innovative therapies with, 1171–1172
- Interleukin-9, for regulation of erythropoiesis, 751**
- Internal medicine, advances in, 1041–1184**

- International travelers, immunizations for, 1277-1294. See also *Immunizations*.  
 Interpersonal relationships, in nicotine dependence program, 510  
 Intestinal flukes, and eosinophilia, in travelers, 1421-1422  
 Intestinal ischemia, surgery for, indications for, 1165  
 Intestinal parasites, in returned travelers, 1433-1448. See also *Parasites*.  
 Intestinal pathogens, in internationally adopted children, 1476  
 Intestine, in *Mycobacterium avium* complex disease, in HIV infection, 139  
 Intracellular killing defects, infections with, 1139  
 Intracranial mass lesions, unsuspected, and hypoxia during flying, 1300-1301  
 Intrathoracic adenopathy, in HIV infection, disorders associated with, 28  
 Iodoquinol, for intestinal amebiasis, 1436  
 Iron, daily dietary intake of, 551  
     deficiency of, and anemia of chronic disease, 571  
     and hypoproliferative anemia, 623  
     in iron deficiency anemia, 558  
     with recombinant human erythropoietin, 719-720  
     for anemia of chronic disease, 576  
     for iron deficiency anemia, 560-562  
     in normal pregnancy, 636-637  
     metabolism of, 549-553  
         absorption, 551-552  
         storage, 552-553  
         transport, 552  
     replacement of, for paroxysmal nocturnal hemoglobinuria, 658  
 Iron-binding capacity, in iron deficiency anemia, 558  
 Ischemia, in peripheral vascular disease, 1160  
 Isolation techniques, for toxoplasmosis diagnosis, in AIDS, 209-210  
 Isoniazid, for tuberculosis, in HIV infection, 140  
 Isosorbide, for advanced heart failure, 10/6  
*Isospora belli*, infection with, in AIDS, 222-224  
     clinical manifestations of, 223  
     diagnosis of, 223  
     diarrhea in, 51-52  
     history and epidemiology of, 222-223  
     pathology and pathogenesis of, 223  
     treatment of, 223-224  
     intestinal, in returned travelers, treatment of, 1439-1440  
 Itraconazole, in HIV infection, for  
     cryptococcal infection, 187  
     for histoplasmosis, 189  
     for oral candidiasis, 182  
 Japanese encephalitis vaccine, for international travelers, 1280, 1284  
 Jaundice, with fever, in returned traveler, 1389-1390  
 Jelly-fish sting, in returning traveler, 1409  
 Jet lag, in pregnant traveler, 1318  
     management of, 1268-1269  
 Kala-azar, in immigrants, 1467-1468  
 Kallikrein, in angioedema, 829  
 Kaposi's sarcoma, in AIDS, 235-252  
     ocular, 93-94  
     spectrum of, 235-236  
     treatment guidelines for, 248  
     treatment options for, 237-247  
         antiviral agents, 244-245  
         bleomycin, 241  
         chemotherapy, 240-243  
             combination, 241-243  
             interferons with, 246-247  
             single agent, 240-241  
         combined modalities, 245-247  
         cryotherapy, 237-238  
         doxorubicin, 241  
         etoposide, 241  
         future directions in, 247-248  
         interferons, 243-244  
             chemotherapy with, 246-247  
             nucleoside reverse transcriptase inhibitors with, 245-246  
         intralesional injections, 238  
         laser therapy, 237  
         local therapy, 237-238  
         observation only, 237  
         radiotherapy, 238-240  
         vinblastine, 240-241  
         vincristine, 241  
         zidovudine, 244-245  
     in HIV infection, bacillary angiomatosis vs, 177  
     pulmonary, 24  
 Karyotypic findings, and survival, in myelodysplastic syndromes, 609  
 Ketoconazole, in HIV infection, for  
     cryptococcal infection, 187  
     for esophageal candidiasis, 182  
     for histoplasmosis, 189  
     for oral candidiasis, 182  
 Ketotifen, for chronic urticaria, 826

- "Kick the Habit", for smoking cessation, 452-453
- Kidney, cancer of, smoking as contributory cause of, 318-319  
rejection of, in pancreas transplantation, 1230  
transplantation of, 1188-1195  
contraindications to, 1189  
donor selection for, 1193-1194  
pancreas transplantation with, 1226  
patient selection for, 1190-1193  
examination for, 1191  
factors affecting, 1190  
special problems in, screening for, 1191-1192  
treatment of, 1192-1193
- Knee, total joint replacement of, 1243-1246
- clinical outcome with, 1246  
complications with, 1244-1245  
component loosening, 1245  
neurologic, 1245  
vascular, 1245
- surgical technique for, 1243-1244
- Lactic dehydrogenase, in intravascular hemolysis, 651  
in pulmonary disease, in HIV infection, 33
- Lactoferrin, in anemia of chronic disease, 573-574
- Laparoscopy, cholecystectomy by, for gallstones, 1149-1155
- Larva currens, in returning travelers, 1402
- Larva migrans, cutaneous, and eosinophilia, in travelers, 1420  
in returning travelers, 1401-1403
- Laryngeal cancer, effect of smoking cessation on, 404  
relative risks of, with smoking and alcohol consumption, 315  
smoking as cause of, 315-316
- Laser angioplasty, for coronary revascularization, 1102-1104  
for vascular occlusion, 1120-1121
- Late-phase responses, to allergen exposure, 769-771
- Latex, allergic reactions to, 876-877  
and IgE-mediated anaphylaxis, 842
- Left ventricular hypertrophy, in hypertension, 1044-1046  
increased risk of, 1044-1045  
nonhemodynamic factors in, 1045  
reversal of, 1045-1046  
traditional concept of, 1044
- Leg ulcers, in sickle cell disease, 677-678
- Leishmaniasis, cutaneous, in returning travelers, 1397, 1399-1400
- visceral, in immigrants, 1467-1468  
with fever, in returned traveler, 1391
- Leprosy, in immigrants, 1473  
in returning travelers, 1404-1405
- Leucovorin, for pneumocystosis, 112, 114
- Leukemia, monocytic, acute, with underlying myelodysplastic syndrome, 607-608  
mortality rates for, 307  
myelomonocytic, chronic, 605  
smoking as contributory cause of, 321-322
- Leukocyte migration, in allergic disease, 906
- Leukoencephalopathy, progressive multifocal, in late HIV infection, 75-76
- Leukotrienes, biologic effects of, 808  
in allergic response, 773  
in virus-induced asthma, 901-902
- Levamisole, for colorectal cancer, 1177
- Lipid levels, effects of pancreas transplantation on, 1229
- Lipoprotein metabolism, effects of smoking on, 341-342
- Lithotripsy, extracorporeal shockwave, for gallstones, 1147-1148
- Liver, abscess of, in amebiasis, in returned travelers, 1435  
cancer of, mortality rates for, 307  
disease of, alcoholic, liver transplantation for, 1224  
peripheral blood smear in, 586  
in HIV infection, cryptococcal infection of, 185  
*Mycobacterium avium* complex disease of, 138  
parasites in, in immigrants, 1471  
transplantation of, 1219-1225  
contraindications to, 1222-1224  
indications for, 1221  
selection process for, 1219-1222
- Liver function tests, in macrocytosis, 587
- Lobeline, for smoking cessation, 456-457
- Loaisis, in returning travelers, 1396, 1406, 1408
- Loperamide, for travelers' diarrhea, 1366-1367
- Loratadine, for urticaria/angioedema, 824-825
- Lung, abscess of, in amebiasis, in returned travelers, 1436  
biopsy of, open, for pulmonary disease, in HIV infection, 36
- Lung cancer, asbestos exposure and, 314  
diet and, 314  
effect of smoking cessation on, 404-405  
environmental factors and, 313  
environmental tobacco smoke and, 381-384

- Lung cancer (*Continued*)  
 histologic type of, in smokers vs non-smokers, 313  
 host factors in, 313  
 innovative therapies in, 1173–1175  
 mortality rates for, 307  
 radon exposure and, 314  
 risk of death from, number of cigarettes smoked and, 312  
 smoking as cause of, 311–315
- Lung disease, smoking-related, 356–360  
 mechanisms for, 360–364  
 mortality from, 356–357  
 pathology in, 358–360  
 susceptibility to, 364
- Lung transplantation, 1207–1219  
 contraindications to, 1211–1214  
 evaluation for, 1214–1216  
 indications for, 1207–1208  
 double, 1210  
 single, 1209–1210  
 options in, specific indications for, 1208–1210  
 patient selection for, 1216–1217  
 recipient criteria for, 1210–1214
- Lyme disease, in returning travelers, 1397
- Lymph node, in *Mycobacterium avium* complex disease, in HIV infection, 137, 139
- Lymphadenitis, tuberculous, in HIV infection, 135
- Lymphadenopathy, with fever, in returned traveler, 1386–1387
- Lymphedema, surgery for, indications for, 1167
- Lymphocyte blast transformation, measurement of, in allergic drug reactions, 863
- Lymphoma, in immunodeficiency, 253–255  
 malignant, AIDS-associated, 253–268  
 epidemiology of, 255–256  
 of central nervous system, 256–258  
 pathologic spectrum of, 258–259  
 systemic, 259–263  
 presenting symptoms and signs of, 259  
 prognostic factors for survival, 261–262  
 sites of, 259–260  
 staging evaluation of, 260–261  
 therapy for, 262–263  
 in autoimmune diseases, 254  
 of eye, in AIDS, 93–94  
 pulmonary, in HIV infection, 24  
 with organ transplantation, 254
- Macrocytosis, causes of, 582–583  
 drug-induced, agents associated with, 585  
 evaluation of, 582–590  
 history taking, 582–585  
 laboratory evaluation, 585–589  
 physical examination, 585  
 incidence of, 582–583  
 significance of, 581–582
- Macrolides, for toxoplasmosis, in AIDS, 213–214
- Magnetic resonance imaging, for toxoplasmosis diagnosis, in AIDS, 211
- Mainstream smoke, components of, 378
- Malabsorption, and iron deficiency anemia, 553  
 in immigrants, 1470
- Malaria, 1327–1355  
 and fever, in returned traveler, 1376–1377
- and hemolytic anemia, 657
- background on, 1327–1328
- chemoprophylaxis for, 1347–1352  
 activities and, 1351  
 age and, 1349  
 in pregnancy, 1319–1322, 1349–1350  
 interactions with other drugs and vaccines, 1350
- itinerary and, 1347–1348
- length of stay and, 1349
- medical history in, 1350
- risk-benefit ratio of, 1352
- side effects of, 1351–1352
- classification of, 1331–1332
- diagnosis of, 1330–1331  
 in special groups, 1344–1345  
 minimum requirements for, 1345–1346
- fever pattern in, 1384
- geographic origin of, 1332
- in immigrants, 1464–1465
- in travelers, 1376–1377, 1397  
 assessment and treatment of, 1353  
 HIV-infected, 1305–1306
- parasitemia in, 1332  
 prevention of, 1346–1352  
 in pregnant traveler, 1319–1322
- prophylaxis for, in children, for international travel, 1308–1309
- rapid identification of, 1329–1331
- risk of, assessment of, 1346–1347
- severe, additional treatment for, 1341  
 chemotherapy of, 1340–1341  
 complications in, 1342–1344  
 definition of, 1332
- species identification of, 1331
- suspicion of, 1329–1330
- terminal radical cure of, primaquine for, 1352–1353
- treatment of, 1329–1332
- Macrocytes, in peripheral blood smear, 586–587

- chemotherapy, 1332-1346  
in special groups, 1344-1345  
minimum requirements for, 1345-1346  
response to, 1344  
uncomplicated, chemotherapy of, 1336-1340  
world distribution of, 1330
- Malignancy(ies), and eosinophilia, in travelers, 1423  
as contraindication to heart transplantation, 1205
- Malignant lymphoma, AIDS-associated, 253-268. See also *Lymphoma*.
- Managed care, role of physicians in, 1037-1038
- Mansonellosis, in returning travelers, 1397
- March hemoglobinuria, and hemolysis, 657
- Mass media programs, for smoking cessation, 465-466
- Mast cells, activators of, nonimmunologic, and anaphylactoid reaction, 845-846  
biology of, 806-807  
in allergic disease, sources of, 778-779  
in chronic urticaria/angioedema, 813-814  
mediators of, 808  
measurement of, in allergic drug reactions, 862  
to allergen, 772-773
- Northern blot test of, 779
- numbers of, effect of grass pollen exposure on, 767
- proliferation of, in atopic disease, 776
- secretagogues of, 806
- Mastocytosis, systemic, anaphylaxis vs, 850
- Mayo Nicotine Dependence Center, 495-514. See also *Nicotine dependence, medical treatment of*.
- Measles/mumps/rubella vaccine, for international travelers, 1289, 1291
- Mecamylamine, for tobacco addiction treatment, 432
- Mecilinam, for travelers' diarrhea prophylaxis, 1363-1364
- Medical assistance, during travel, 1267
- Medical kit, for travel, 1261-1276  
in pregnancy, 1323  
symptom-oriented, 1264-1266
- Medication(s), availability of, in Eastern Europe, 1306-1307  
history of, in chronic urticaria/angioedema, 816  
in smoking cessation, 456-458
- Medicine, high altitude, 1481-1497
- Mefloquine, for malaria, 1333-1334, 1339  
in pregnant traveler, 1321  
prevention with, side effects of, 1351
- Megaloblastic crisis, in sickle cell disease, 674
- Melioidosis, in immigrants, 1466
- Meningitis, aseptic, in early HIV infection, 65-66
- Meningococcus vaccine, for international travelers, 1280, 1285
- Metabolic acidosis, in pancreas transplantation, 1230
- Metabolism, effects of smoking on, 341-342
- Metallic salts, and occupational asthma, 928-929
- Methacholine inhalation test, for occupational asthma, 921
- Methotrexate, for asthma, 965-969  
future application of, 968-969  
present application of, 967-968
- Methyl-CCNU, for colorectal cancer, 1177
- Methyl-tertiary-butyl ether, for gallstone therapy, 1146-1147
- Methylprednisolone, for asthma, 960
- Metronidazole, for intestinal amebiasis, 1436
- Miconazole, for esophageal candidiasis, in HIV infection, 182
- Microcytic anemia, 549-566. See also under *Anemia(s)*.
- Microcytic state, laboratory evaluation of, 555
- Microspherocytes, in peripheral blood smear, 588
- Microsporidia, and diarrhea, in AIDS, 52-53
- Milrinone, for advanced heart failure, 1073
- Mite allergens, physicochemical properties of, 942
- Molds, as indoor allergens, 939
- Molecular medicine, applications of, 1029  
development of, 1027-1028  
in multispecialty clinic, 1030
- Monoclonal antibodies, medical applications of, 1029
- Monocyte colony stimulating factor (M-CSF), innovative therapies with, 1171
- Mononuclear phagocytic cells, in allergic disease, sources of, 780-781
- Morbidity, smoking cessation and, 403-404
- Mortality, smoking cessation and, 401-403
- Mosquitoes, malaria-bearing, contact with, reduction of, 1347
- Motion sickness, in pregnant traveler, 1317-1318  
management of, 1269-1270
- Mountain sickness, acute, 1484  
treatment of, 1488
- Mucous secretion, increased, in anaphylaxis, 849

- Multicomponent programs, for smoking cessation, 459-460
- Multiple sclerosis-like illness, in early HIV infection, 65
- Multiprofessional clinic(s), 1002-1039  
academic pursuits in, 1003-1006  
appeal to specialists, 1019  
development of, 1015  
family medicine in, 1036  
future of, 1039  
health care delivery by, 1015-1020  
health maintenance organization in, 1036  
in changing environment, 1035-1039  
innovative therapies in, 1025-1033  
patient hospitalization in, 1016  
patient mix in, 1017  
personalized care in, 1017  
profile of, 1017-1018  
regional health care by, 1019  
reimbursement problems of, 1018  
research and education in, 1016  
satellite clinics of, 1036  
staffing patterns of, 1016
- Multispecialty group, graduate education in, 1021-1024  
current practice modes of, 1024  
health care adaptability of, 1023-1024  
patient care in, 1022-1023  
patient orientation of, 1022
- Muscle relaxants, allergic reactions to, 872-873
- Muscle relaxation, effect of nicotine on, 422
- Musculoskeletal disorders, as contraindication to lung transplantation, 1212
- Musculoskeletal pain, in sickle cell disease, 672
- Mycobacterial infection, in HIV infection, 23, 121-171  
nontuberculous, 158-159
- Mycobacterium avium-intracellulare*, and diarrhea, in AIDS, 55-56  
in HIV infection, 147-158  
and decreased red blood cell production, 703  
bacteriology of, 152-154  
blood culture of, 152-153  
clinical features and diagnosis of, 151-154  
epidemiology and pathogenesis of, 149-151  
pathology of, 154  
prevention of, 156  
sputum tests of, 153  
stool tests of, 153  
treatment of, 154-158  
clinical approach to, 155-156  
future prospects for, 156
- Mycobacterium avium-intracellulare* complex disease, disseminated, in AIDS, prevalence of, 150-151  
in AIDS vs non-AIDS patients, 148  
in HIV infection, immune regulation and modulation in, 157-158  
intestinal section from, 139  
liver section from, 138  
lymph node section from, 137, 139  
prevalence of, 148
- Mycoplasma* infection, and immune hemolytic anemia, 655
- Mycoses, in HIV infection, 178-192
- Myelodysplasia, FAB classification of, 595  
macrocytic red cells in, 589  
peripheral blood smear in, 587
- Myelodysplastic syndromes, 595  
blood transfusions for, 735-736  
causes of death in, 607  
clinical features of, 603  
definition of, 599  
evolution of, 600  
future considerations in, 613  
hematologic features of, 603-606  
in elderly, 629  
natural history of, 606-608  
pathogenesis of, 600-603  
prognostic features in, 608-609  
secondary, relation to acute leukemia, 607  
survival in, by FAB subgroup, 608  
treatment of, 609-613  
bone marrow transplantation, 611  
cytotoxic therapy, 610-611  
differentiating agents, 611-612  
empiric therapy, 610  
supportive care, 609-610
- Myiasis, in returning travelers, 1406-1407
- Myocardial contractility, decrease in, in advanced heart failure, 1060
- Myocardial hypertrophy, with chronic anemia, 728
- Myocardial hypertrophy/dilatation, in advanced heart failure, 1061-1062
- Myocardial infarction, antihypertensive treatment and, 1047-1050  
J-shaped curve phenomenon in, 1049-1050  
patient history of, and high altitude travel, 1491  
percutaneous transluminal coronary angioplasty in, 1087  
risk of, effect of smoking cessation on, 406-407
- Myocardial oxygen demand, smoking and, 339
- Myocarditis, in severe malaria, 1343-1344
- Myocardium, candidiasis of, in HIV infection, 181  
cryptococcosis of, in HIV infection, 184

- revascularization of, 1083–1097  
 angioplasty vs bypass surgery for, 1083–1085  
 conditions affecting, 1089  
 decision for, 1085–1086
- Myopathies**, in late HIV infection, 73–74
- Narcotics**, allergic reactions to, 845, 873
- Nasal saline**, for allergic rhinitis, 799
- Nasal spray**, nicotine, for tobacco addiction treatment, 432
- Nedocromil sodium**, for allergic rhinitis, 798  
 for asthma, 959
- Neisseria gonorrhoeae***, antibiotic resistance in, prevalence of, 1451
- Nematode infections**, and eosinophilia, in travelers, 1417–1420
- Neoplasia**, and anemia of chronic disease, 568  
 and immune hemolytic anemia, 653–654
- Neoplasms**, neurologic manifestations of, in late HIV infection, 74–75
- Nephropathy**, diabetic, effects of pancreas transplantation on, 1228
- Nervous system abnormalities**, in HIV infection, 63–81  
 approach to diagnosis of, 76–77  
 clinical presentation of, 77  
 early, 65–67  
 late, 67–76  
 principles of, 63–64
- Neuro-ophthalmic complications**, of AIDS, 95
- Neuroendocrine function**, effect on heart, 1063–1064
- Neurogenic inflammation**, in allergic disease, 781–782
- Neuroleptics**, for psychiatric disturbances, in HIV infection, 103
- Neurologic disorders**, in early HIV infection, 65–67  
 in high altitude traveler, 1492  
 in immigrants, 1474–1475  
 in late HIV infection, 74  
 with fever, in returned traveler, 1390  
 with total hip replacement, 1240
- Neuromuscular disorders**, as contraindication to lung transplantation, 1212
- Neuromuscular relaxing agents**, and anaphylactoid reaction, 845
- Neuropathy**, diabetic, effects of pancreas transplantation on, 1229
- Neuropeptides**, effects in allergic disease, 781
- Neuropsychological dysfunction**, in early HIV infection, 66
- Neuroradiologic studies**, for toxoplasmosis diagnosis, in AIDS, 211
- Neutral proteases**, biologic effects of, 808 in allergic response, 772
- Neutropenia**, infections with, 1139
- Neutrophil chemotactic factor**, biologic effects of, 808  
 in allergic response, 772
- Nickel**, and erythropoietin production, 747
- Nicorette**. See *Nicotine polacrilex (Nicorette)*.
- Nicotine**, absorption of, 419–420  
 addiction to. See *Nicotine addiction*.  
 dependence on. See *Nicotine dependence*.  
 distribution of, 420–421  
 intake of, regulation of, 425  
 pharmacodynamics of, 421–422  
 pharmacology of, addiction and, 418–422  
 implications for treatment, 431–434  
 role in maintaining cigarette smoking, 423–425  
 tolerance to, 422–427  
 withdrawal from, 421–427
- Nicotine addiction**, alcohol addiction vs, 430  
 attributes of, 428  
 caffeine addiction vs, 430  
 cigarette smoking and, 415–437  
 comparison to other drug addictions, 427–430  
 cycle of, 422–424  
 free will vs, 425–427  
 heroin addiction vs, 430  
 relapse after abstinence from, 428–429  
 Nicotine dependence, DSM-IIIR criteria for, 501  
 medical treatment of, model for, 495–514  
 adjunctive pharmacologic therapy in, 506–508  
 consultation program in, 498–509  
 referring physician's role, 498–500  
 relapse prevention, 508–509  
 treatment plan, 502–509  
 follow-up program in, 509–513  
 group intervention, 509–510  
 individual counseling, 509  
 inpatient treatment, 511–513  
 outpatient program, 510–511  
 support group, 513  
 overview of, 495–498  
 reimbursement for, 512–513  
 patient characteristics in, 497–498  
 withdrawal symptoms in, 506
- Nicotine dependence counselor**, function of, 500
- Nicotine fading**, for smoking cessation, 459

- Nicotine gum. See *Nicotine polacrilex (Nicorette)*.
- Nicotine nasal spray, for tobacco addiction treatment, 432
- Nicotine patch, for smoking cessation, 458, 487  
for tobacco addiction treatment, 431, 507
- Nicotine polacrilex (Nicorette), for smoking cessation, 457–458  
technique of using, 486–487, 507  
for tobacco addiction treatment, 431, 506–507
- Nifedipine, for altitude illness syndromes, 1488  
for chronic urticaria, 826
- Nitrates, for advanced heart failure, 1075–1076
- Nitrogen oxides, as indoor air pollutants, 937, 945
- Nocardiosis, in HIV infection, 23
- Norfloxacin, for travelers' diarrhea prophylaxis, 1363–1364
- Northern analysis, medical applications of, 1029
- Nuclear histologic grading, in breast cancer, 1176
- Nucleotide enzyme defects, and hemolytic anemia, 663
- Nystatin, for esophageal candidiasis, in HIV infection, 182
- Obesity, as contraindication to lung transplantation, 1212
- Obstetric concerns, in high altitude traveler, 1493–1494
- Obstructive airway disease, virus-induced, mechanisms of, 899–911
- Occupational asthma, 917–934  
causative agents in, 918, 924–930  
diagnosis and assessment of, 919  
differential diagnosis of, 923–924  
immunologic testing in, 922–923  
occupational history in, 919–921  
pathophysiologic mechanisms in, 918  
physiologic testing in, 921–922  
prevention and treatment of, 930–931
- Occupational Safety and Health Administration, report on environmental tobacco smoke, 529
- Ochsner, Alton, contributions of, 1007–1013
- Ochsner Clinic(s), founding of, 1007  
mission and structure of, 1005  
reorganization of, 1035–1036
- Ocular toxoplasmosis, in AIDS, 91, 208
- Odynophagia, in AIDS, 45
- Onchocerciasis, in returning travelers, 1395–1396, 1406–1407
- Oncogenes, and cytogenetic abnormalities, 602  
in myelodysplastic syndromes, 601–603
- Oncology, innovative therapies in, 1169–1184
- Ophthalmic problems, in AIDS, 83–97
- Ophthalmologic diseases, in immigrants, 1474
- Opportunistic infections, in HIV infection, 173–203  
neurologic manifestations of, 74–75  
of retina, in AIDS, 91
- Optic neuropathy, cytomegalovirus, in AIDS, 87
- Oral cancer, effect of smoking cessation on, 406  
smoking as cause of, 317
- Organ dysfunction, as contraindication to heart transplantation, 1203–1205
- Organ transplantation, patient selection for, 1187–1233
- Organic compounds, volatile, as indoor air pollutants, 938, 945
- Oropharyngeal candidiasis, in HIV infection, 179–180
- Ossification, heterotopic, with total hip replacement, 1239
- Osteodystrophy, hepatic, liver transplantation for, 1220
- Outcome analysis, statistical, in multispecialty clinic, 1032
- Ovarian cancer, prevention of, 1180
- Oxygen, for sickle cell crisis, 673  
maximum consumption of, in heart transplantation candidate, 1199
- Pain, as indication for total joint replacement, 1235  
control of, in sickle cell crisis, 673  
in peripheral vascular disease, 1160
- Pancreas, cancer of, effect of smoking cessation on, 406  
mortality rates for, 307  
smoking as contributory cause of, 319–320
- disorders of, in AIDS, 48  
transplantation of, 1225–1233  
benefits of, 1228–1229  
risks of, 1230  
selection criteria for, 1227–1228
- Pancytopenia, differential diagnosis of, 683–684
- Papules, in returning travelers, 1395
- Papulosquamous lesions, in returning travelers, 1398

- Paragonimiasis, and eosinophilia, in travelers, 1421
- Parainfluenza virus infection, and asthma, 900  
effect on airway epithelium, 909
- Parasites, infections with, in HIV-infected traveler, 1305  
intestinal, in immigrants, 1469–1470  
in returned travelers, 1433–1448  
liver, in immigrants, 1471
- Paratracheal adenopathy, in pulmonary tuberculosis, in HIV infection, 129–130
- Paresthesia, in peripheral vascular disease, 1160
- Paromomycin, for intestinal amebiasis, 1436
- Paroxysmal cold hemoglobinuria, 656
- Paroxysmal nocturnal hemoglobinuria, 658
- Passive smoking. See *Tobacco smoke, environmental*.
- Patellofemoral pain, with total knee replacement, 1244–1245
- Patient care, in graduate education multispecialty group, 1022–1023  
in multispecialty clinic, 1004, 1038
- Patient characteristics, at Mayo Nicotine Dependence Center, 497–498
- Penicillin, allergic reactions to, 863–866  
desensitization protocol for, 867–868  
skin tests for, 865  
anaphylactic reaction to, 843  
and immune hemolytic anemia, 655
- Pentamidine, for pneumocystosis, 112–115  
for pneumocystosis prophylaxis, 114–116
- Peptic ulcer disease, as contraindication to heart transplantation, 1204
- Pericarditis, in pulmonary tuberculosis, in HIV infection, 130
- Peripheral blood smear, in hemolysis, 650  
in HIV-associated anemia, 700–701  
in iron deficiency anemia, 555–557
- Peripheral neuropathy, in HIV infection, 64, 73
- Peripheral vascular changes, in advanced heart failure, 1065
- Peripheral vascular disease, as contraindication to heart transplantation, 1205  
history in, 1159–1161  
percutaneous intervention for, 1110  
plethysmography in, 1163  
revascularization surgery for, options for, 1099–1124  
patient selection for, 1159–1168  
smoking and, 346–347
- Peripheral vascular resistance, reduced, in anaphylaxis, 849
- Peritonitis, bacterial, recurrent spontaneous, liver transplantation for, 1220
- Personality factors, in nicotine addiction, 418–419
- Pertussis vaccine, for international travelers, dosing schedule for, 1289
- Pets, and indoor allergens, 939
- Phagadenic ulcer, tropical, in returning travelers, 1399–1400
- Phagocytic system, defects in, infections with, 1139–1141
- Pharmaceutical agents, for smoking cessation, 456–457
- Pharmacologic therapy, at Mayo Nicotine Dependence Center, 496
- Phosphodiesterase inhibitors, for advanced heart failure, 1073
- Physical dependence, in nicotine addiction, 429
- Physician, counseling by, in smoking cessation, 460–462  
locating during travel, 1266
- Phytodermatitis, in returning travelers, 1398
- Phytophotodermatitis, in returning travelers, 1402–1405
- Pigmentation, disorders of, in returning travelers, 1403–1405
- Pinta, in returning travelers, 1405
- Pipe smoking, and lung cancer, 312  
trends in, 297–298
- Piritrexim, for toxoplasmosis, in AIDS, 214
- Pityriasis alba, in returning travelers, 1405
- Plague, in returning travelers, 1397  
vaccine for, for international travelers, 1280, 1285
- Plasma volume, increase in, in pregnancy, 631–633
- Plasmodium falciparum*, chemotherapy of, 1337–1338, 1340
- Plasmodium malariae*, chemotherapy of, 1336–1337, 1339
- Plasmodium ovale*, chemotherapy of, 1337, 1339
- Plasmodium* species, life cycle of, 1328–1329
- Plasmodium vivax*, chemotherapy of, 1337, 1339
- Platelet-activating factor, biologic effects of, 808  
in allergic response, 773
- Platelet activity, effects of smoking on, 340–341
- Plesiomonas*, and travelers' diarrhea, 1361
- Plethysmography, in peripheral vascular disease, 1163
- Pleural effusion, in HIV infection, disorders associated with, 28  
in pulmonary tuberculosis, 129

- Pneumatocele, in HIV infection, disorders associated with, 28
- Pneumococcus, and wheezing, 897  
vaccine for, for international travelers, 1289, 1292–1293
- Pneumocystis carinii*, in sputum, 35  
infection with, following heart transplantation, 1131–1132  
retinal, in AIDS, 91  
pneumonia caused by. See *Pneumocystosis*.  
prophylaxis against, in HIV infection, 36–37
- Pneumocystosis, in HIV infection, 20–21, 29, 107–119  
diagnosis of, 110–112  
differential, 111  
signs and symptoms, 110–111  
tests and procedures, 111–112  
epidemiology of, 108–109  
pathogenesis and pathology of, 108  
treatment of, 112–115  
prevention of, 114–117  
prophylaxis of, 114
- Pneumonia, cigarette smoking and, 370–371  
in HIV infection, bacterial, 21–22, 175  
*Pneumocystis carinii*, 20–21  
in severe malaria, 1343  
mortality from, effect of smoking cessation on, 408
- Pneumonitis, interstitial, in HIV infection, 24–25
- Poliomyelitis vaccine, for international travelers, 1289–1291
- Polychromatophilia, in peripheral blood smear, 588
- Polymerase chain reaction, for HIV infection diagnosis, 8  
for toxoplasmosis diagnosis, in AIDS, 211  
medical applications of, 1029
- Polymerophenuclear function, effect of respiratory viruses on, 906
- Prednisone, for asthma, 960
- Preeclampsia, hemolytic anemia with, in pregnancy, 642–643
- Pregnancy, anemia in, 631–647. See also under *Anemia(s)*.  
in sickle cell disease, 679  
physiologic changes in, 631–634  
travel in. See *Pregnant traveler*.  
urticaria/angioedema in, 823
- Pregnant traveler, 1313–1326  
accidents to, 1322–1323  
aquatic hazards to, 1322  
diarrhea in, 1316–1317  
environmental hazards to, 1317  
food and water for, 1316  
high altitude travel by, 1322, 1493–1494  
immunizations for, 1314–1316  
insect bites of, 1318–1319  
jet lag in, 1318  
laboratory work on, 1314  
malaria in, diagnosis and treatment of, 1344–1345  
prevention of, 1319–1322, 1349–1350  
medical and social history in, 1314  
medical kit for, 1323  
motion sickness in, 1317–1318  
physical examination of, 1314  
posttravel evaluation of, 1323  
sexually transmitted diseases in, 1323  
sun exposure of, 1318  
travel plans of, 1313
- Preleukemia, concept of, 606
- Prescription medicine, for travel, 1266
- Pressure changes, during travel, management of, 1271–1272
- Primaquine, for malaria, 1335–1336, 1339  
prevention with, in pregnant traveler, 1319  
side effects of, 1351–1352  
terminal radical cure with, 1352–1353  
for pneumocytosis, 112–113
- Progressive multifocal leukoencephalopathy, in late HIV infection, 75–76
- Proguanil, for malaria, 1336  
in pregnant traveler, 1319–1320  
prevention with, side effects of, 1351
- Prostaglandins, biologic effects of, 808  
in allergic response, 773
- Prostate, cancer of, mortality rates for, 307  
prevention of, 1180  
cryptococcal infection of, in HIV infection, 185
- Protamine, allergic reactions to, 873–876
- Protease-antiprotease hypothesis, of emphysema development, 363–364
- Proteins, and occupational asthma, 926
- Proteoglycans, in allergic response, 772
- Proto-oncogenes, in myelodysplastic syndromes, 601–602
- Protoporphyrin, free erythrocyte, in iron deficiency anemia, 558
- Protozoan infections, and eosinophilia, in travelers, 1415–1416  
following heart transplantation, 1131  
intestinal, in returned travelers, 1434–1443
- Pruritus, in anaphylaxis, 847
- Pseudomonas aeruginosa* infection, following heart transplantation, 1129
- Psychiatric disturbances, in HIV infection, 99–106  
medical condition and, 99–100  
therapies for, 101–105  
pharmacotherapy, 101–103  
psychotherapy, 103–105

- Psychoactive substance, dependence on, American Psychiatric Association criteria for, 417
- Psychoeducation, for psychiatric disturbances, in HIV infection, 104–105
- Psychosocial evaluation, of heart transplantation candidate, 1201
- Psychosocial problems, as contraindication to lung transplantation, 1212
- Psychosocial support, for psychiatric disturbances, in HIV infection, 104
- Psychostimulants, for psychiatric disturbances, in HIV infection, 103
- PTCA. See *Coronary angioplasty, percutaneous transluminal*.
- Public places, smoking in, state limitations on, 387, 518
- Public policy, for control of tobacco-related disease, 515–539
- Pulmonary capillaries, alterations in, cigarette smoking and, 359
- Pulmonary capillary wedge pressure, in heart transplantation candidate, 1200
- Pulmonary disease(s), and travel, 1295–1299
- as contraindication to flying, 1298
  - as contraindication to heart transplantation, 1203–1204
  - cigarette smoking and, 355–375
  - in high altitude traveler, 1492
  - in HIV infection, 19–44
    - approach to, 19
    - assessment of patient with, 26–31
    - causes of, infectious, 19–23
      - noninfectious, 23–25
    - chest radiograph in, 28–31
    - diagnostic approach to, 31–36
      - bronchoscopy, 34–36
      - open lung biopsy, 36
      - screening tests, 31–32
      - sputum analysis, 33–34
    - history and examination in, 26–27
    - laboratory values in, 27
    - prophylactic considerations in, 36–39
    - spectrum of, 19–26
    - symptom development in, 27
  - in immigrants, 1471–1472
  - in sickle cell disease, 674–675
- Pulmonary edema, high altitude, 1485 treatment of, 1488–1489
- in HIV infection, 26
  - in severe malaria, 1343
- Pulmonary emboli, after prolonged flying, 1300
- Pulmonary fibrosis, lung transplantation for, 1207
- Pulmonary function, cigarette smoking and, 364–367
- testing of, in pneumocystosis, 111
- in pulmonary disease, in HIV infection, 32
- Pulmonary hypertension, as contraindication to heart transplantation, 1202
- in high altitude travelers, 1482
  - lung transplantation for, 1207, 1209–1210
- Pulmonary syndromes, and eosinophilia, in travelers, 1423
- Pulmonary thromboemboli, in HIV infection, 26
- Pulmonary vascular disease, heart-lung transplantation for, 1208–1209
- Purine analogue, for toxoplasmosis, in AIDS, 214
- Purpura, post-transfusion, 740
- thrombotic thrombocytopenic, and hemolytic anemia, 656–657
- Pyoderma, in returning travelers, 1399
- Pyrazinamide, for tuberculosis, in HIV infection, 140
- Pyrimethamine, for malaria prevention, in pregnant traveler, 1319–1320
- for toxoplasmosis, in AIDS, 211–212
- Pyrimethamine-sulfadoxine, for malaria, 1334, 1338–1339
- prevention with, side effects of, 1351
  - for pneumocystosis prophylaxis, 114, 116
- Pyropoikilocytosis, hereditary, and hemolytic anemia, 660
- 5q-syndrome, in myelodysplastic syndromes, 602
- Quality of life, improvement in, with recombinant human erythropoietin, 717
- Quinidine, for malaria, 1335, 1338
- prevention with, in pregnant traveler, 1321
- Quinine, for malaria, 1334–1335, 1338
- prevention with, in pregnant traveler, 1320–1321
- Quinolones, for travelers' diarrhea, 1366–1368
- Quit for Good Kit*, for smoking cessation, 453
- Rabies vaccine, for international travelers, 1280, 1285–1286
- Radiation, exposure to, and myelodysplastic syndromes, 601
- therapy with, for breast cancer, 1176
  - for colorectal cancer, 1177
  - for lung cancer, 1174

- Radio programs, for smoking cessation, 465-466
- Radioallergosorbent test, for allergic drug reactions, 861-862
- Radiocontrast media, allergic reactions to, 843, 845, 869-870
- Radon, as indoor air pollutant, 937-938, 945  
exposure to, and lung cancer, 314
- Ragweed antigen, airway response to, rhinovirus respiratory infection and, 904
- Ranitidine, for acute anaphylaxis, 851
- Rash, with fever in returned traveler, 1385-1386
- Receptor antagonists, for tobacco addiction treatment, 432
- Red blood cells, decreased survival of, in anemia of chronic disease, 572  
enzyme defects in, and hemolytic anemia, 661-663  
in HIV-associated anemia, decreased production of, 701-705  
drug treatment and, 703-704  
HIV related, 701-703  
other infections and, 703  
vitamin deficiencies and, 704  
destruction/sequestration of, 704  
increased mass of, in pregnancy, 632-633
- macrocytic, on peripheral blood smear, 589
- membrane of, inherited defects of, 659-661
- precursors of, in bone marrow aspirate, 584
- production of, erythropoietin regulation of, 713
- toxic effects on, and hemolysis, 657-658
- transfusion of, autologous, 741  
choice of blood products for, 732  
directed donations for, 741  
for HIV-associated anemia, 706  
for paroxysmal nocturnal hemoglobinuria, 658  
homologous, alternatives to, 741-742  
minimal exposure, 741-742  
pharmacologic alternatives to, 742
- Relapse prevention, at Mayo Nicotine Dependence Center, 496
- Relapsing fever, in immigrants, 1467  
in returning travelers, 1397
- Renal artery, angioplasty of, 1117  
occlusive disease of, surgery for, indications for, 1165
- Renal disease, as contraindication to heart transplantation, 1204  
as contraindication to lung transplantation, 1211
- end-stage, and essential hypertension, 1050-1052
- Renal failure, anemia of, 711-725. See also under *Anemia(s)*  
in severe malaria, 1342-1343
- Renal insufficiency, and anemia of chronic disease, 571-572
- Renal transplantation, 1188-1195. See also *Kidney transplantation*.
- Renin-angiotensin system, in advanced heart failure, 1064-1065
- Reproduction, effect of smoking cessation on, 410-411
- Research, in multispecialty clinic, 1005, 1039
- Respiratory burst products, in allergic response, 773
- Respiratory conditions, cigarette smoking and, 367-371  
studies of, 368-369  
symptoms in, 367-369
- Respiratory disease, cigarette smoking and, 370-371  
in pneumocystosis, 110  
nonmalignant, effect of smoking cessation on, 407-410
- Respiratory infection(s), and asthma, 895-915  
therapeutic approaches to, 911-913  
epidemiology of, 895-896  
rhinovirus, effect of ragweed antigen in, 904  
effect on airway reactivity, 903  
viral, and airway hyperreactivity, 896-898  
and late-phase asthmatic response, 902-906  
bronchoconstriction with, mechanisms of, 912  
effect on cellular immune response, 910-911  
effect on polymorphonuclear function, 906  
with fever, in returned traveler, 1388-1389
- Respiratory syncytial virus, and asthma, 899
- nasopharyngeal secretions following, histamine content of, 901
- leukotriene release in, 902
- Restlessness, with acute anemia, 728
- Restriction fragment length polymorphisms, medical applications of, 1029
- Reticulocyte count, in hemolysis, 650  
in HIV-associated anemia, 700  
in macrocytosis, 587
- Retina, in AIDS, 83-92  
hemorrhage of, 85  
microangiopathy of, 83-85  
toxoplasmosis of, 208

- viral infections of, 90-91
- Retinchoroiditis, toxoplasmic, with cytomegalovirus retinitis, 92**
- Retinoic acid analogs, for myelodysplastic syndromes, 611-612**
- Retinopathy, diabetic, effects of pancreas transplantation on, 1229**
  - high altitude, 1486
  - treatment of, 1489
  - noninfectious, in AIDS, 83-85
- Retroviruses, features of, 5**
  - in travelers, 1454-1455
- Revascularization surgery, peripheral, patient selection for, 1159-1168**
- Rhinitis, allergic, 789-803. See also *Allergic rhinitis*.**
- Rickettsial infections, in immigrants, 1467**
  - in returning travelers, 1399
- Rifabutin, for *Mycobacterium avium-intracellulare*, in HIV infection, 155**
- Rifampin, in HIV infection, for *Mycobacterium avium-intracellulare*, 156**
  - for tuberculosis, 140
- Right heart catheterization, in heart transplantation candidate, 1200**
- Roundworm, in immigrants, 1469-1470**
- Roxithromycin, for toxoplasmosis, in AIDS, 214**
- Rubber, allergic reactions to, 876-877**
  
- Saline, nasal, for allergic rhinitis, 799**
- Salmonella, and diarrhea, in AIDS, 56**
  - and travelers' diarrhea, 1360
- Satellite clinics, of multispecialty clinic, 1036**
- Satiation therapy, for smoking cessation, 458**
- Scabies, in returning travelers, 1395, 1397**
- Schick Centers for Control of Smoking, smoking cessation program of, 455-456**
- Schilling test, abnormal, conditions associated with, 593**
  - in anemia, in elderly, 628
  - in cobalamin deficiency, 592-593
- Schistocytes, in peripheral blood smear, 588**
- Schistosomiasis, in travelers, and eosinophilia, 1420-1421**
  - management of, 1272-1273
  - returning, 1408
- Schools, smoking prevention programs in, physician's role in, 445-447**
- Scrub typhus, in returning travelers, 1396, 1399**
- Sea anemone sting, in travelers, 1409**
  
- Sea urchin envenomation, in travelers, 1409**
- Seizures, at high altitude, 1492**
  - in late HIV infection, 74
  - in severe malaria, 1342
  - with recombinant human erythropoietin, 718
- Self-care, in smoking cessation, 452-454**
- Self-management techniques, for smoking cessation, 458-459**
- Serum sickness, anaphylaxis vs, 850**
- Seventh-day Adventist Church, smoking cessation program of, 455**
- Sexual potency, recovery of, with recombinant human erythropoietin, 717**
- Sexually transmitted diseases, in immigrants, 1472**
  - in travelers, 1449-1461
  - HIV-infected, 1306
  - pregnant, 1323
  - prevention of, 1455-1456
  - prevalence of, worldwide, 1450
  - traditional, 1449-1452
- Shigellosis, and diarrhea, in AIDS, 56**
  - and travelers' diarrhea, 1360
- Shock, in severe malaria, 1343-1344**
- Sickle cell anemia, and hemolytic anemia, 665**
  - in pregnancy, 644
- Sickle cell crisis, in sickle cell disease, 672-673**
- Sickle cell disease, 669-682**
  - aplastic/megaloblastic crisis in, 674
  - blood transfusions for, 736
  - bone in, 677
  - central nervous system in, 676-677
  - clinical features of, 671-678
  - etiology and pathogenesis of, 669-670
  - eyes in, 678
  - genitourinary system in, 675-676
  - hepatobiliary system in, 674
  - leg ulcers in, 677-678
  - pregnancy in, 679
  - pulmonary disease in, 674-675
  - sickle cell crisis in, 672-673
  - splenic sequestration crisis in, 673-674
  - supportive therapy for, 678
  - surgery for, 678-679
  - systemic manifestations of, 671-672
  - vaso-occlusive events in, 672-673
- Sickle cell trait, and hemolytic anemia, 665**
  - in pregnancy, 644
- Sickling, interaction with thalassemia, 670**
- Sideroblasts, ringed, in refractory anemia, 605**
- Sidestream smoke, components of, 378**
- Sinus disease, characteristics of, pre- and post treatment, 898**

- Sinusitis, and airway hypersensitivity, 898-899
- Skin disorders, during travel, management of, 1271  
in immigrants, 1473-1474  
in returning travelers, 1393-1411  
linear lesions, 1401-1403  
swellings, 1404, 1406-1408  
ulcers, 1398-1401  
tropical, epidemiology of, 1394
- Skin patch, nicotine, for smoking cessation, 431, 457-458, 486-487, 507
- Sleeping sickness, in returning travelers, 1397
- Small airway function, tests of, 365-366
- Smart Move*, for smoking cessation, 452
- Smoke Stoppers, smoking cessation program of, 456
- Smokeless, smoking cessation program of, 456
- Smokeless tobacco, use of, trends in, 298-299
- SmokEnders, smoking cessation program of, 455
- Smokers, current vs former, lung cancer risk in, 405  
mortality rates among, 402  
probability of death among, 403  
former, characteristics of, 401  
in clinical practice, identification and counseling of, 489
- Smoking. See *Cigarette smoking*.
- Smoking cessation, among clinic patients, clinician's role in, 477-494  
and body weight change, 411  
and cardiovascular disease, 406-407  
and lung cancer risk, 312  
and nonmalignant respiratory disease, 407-410  
and nonrespiratory cancer, 405-406  
and overall morbidity/mortality, 401-403  
and reproduction, 410-411  
and respiratory cancer, 404-405  
and respiratory symptoms, 408  
behavior change in, 478  
clinical trials of, 480-483  
effects on abdominal aortic aneurysm, 347  
effects on cerebrovascular disease, 346  
effects on coronary heart disease, 343-345  
effects on peripheral vascular disease, 346-347  
follow-up on, 487  
good reasons for, 485  
health benefits of, 399-414  
health consequences of, 401-412  
information provision in, 486  
lack of social support for, management of, 492  
methods of, 451-476  
acupuncture, 463-465  
behavioral, 458-460  
clinics and groups, 454-456  
commercial, 455-456  
voluntary agencies for, 454-455  
community programs, 466-468  
comparison of quit rates, 468-470  
current approaches to, 452  
early programs for, 451-452  
hypnosis, 462-463  
mass media programs, 465-466  
medication, 456-458  
physician advice and counseling, 460-461  
self-care, 452-454
- National Cancer Institute recommendations for physicians, 483-489  
office organization, 487-489  
physician intervention, 483-487
- National Cancer Institute research on, 470-471  
patient motivation in, 480  
pharmacologic therapy for, 486  
physician training in, effectiveness of, 482  
problems and solutions in, 490-492  
programs for, reimbursement for, 525-526  
psychological and behavioral consequences of, 411  
quit date for, selection of, 485-486  
relapses with, management of, 428-429, 490-491  
stages of, 478-479, 501  
treatment plans for, 504-505  
stepped-care approach to, 433-434
- Surgeon General's recommendations on, 412  
team approach to, 487-489  
theoretical background on, 478-480  
trends in, 296-297, 400
- Smoking prevention programs, physician's role in, 445-447
- Smoking-related disease, control of, public policy for, 515-539
- Smooth muscle cell proliferation, and atherosclerosis, effect of smoking on, 338
- Smooth muscle contraction, in anaphylaxis, 849
- Snake bite, during travel, management of, 1270
- Southern analysis, medical applications of, 1029
- Spherocytosis, hereditary, and hemolytic anemia, 659-660

- Spider bite, brown recluse, in returning travelers, 1399–1400
- Spiramycin, for toxoplasmosis, in AIDS, 213
- Splenectomy, for immune hemolytic anemia, 654
- Splenic rupture, in severe malaria, 1344
- Splenic sequestration crisis, in sickle cell disease, 673–674
- Splenomegaly, causes of, 652  
in hemolysis, 650  
with fever, in returned traveler, 1386
- Sputum analysis, for pulmonary disease, in HIV infection, 33–34
- Staphylococcal infections, following heart transplantation, 1128
- Staphylococcus aureus*, and wheezing, 897
- Stem cell defect, in anemia of chronic disease, 572–573
- Stents, for coronary revascularization, 1104–1105  
for vascular occlusion, 1120
- Steroids, as contraindication to lung transplantation, 1213  
for paroxysmal nocturnal hemoglobinuria, 658
- Stinging insect allergy, 883–894. See also *Insect stings, allergy to*
- Stomach cancer, mortality rates for, 307  
smoking as contributory cause of, 320
- Stomatocytosis, hereditary, and hemolytic anemia, 660–661
- Storage mites, as indoor allergens, 939–942  
environmental control of, 946–948
- Streptococcus*, beta-hemolytic, and wheezing, 897
- Streptokinase, allergic reactions to, 875–876  
for chronic extremity ischemia, 1114
- Stress management, in nicotine dependence program, 510
- Stroke, in late HIV infection, 74  
in sickle cell disease, 676–677  
risk of, effect of smoking cessation on, 407
- Stroke volume, in heart transplantation candidate, 1200
- Strongyloidiasis, intestinal, in immigrants, 1469  
in returned travelers, 1444–1445
- Subclavian artery, angioplasty of, 1116–1117
- Sulfadiazine, for toxoplasmosis, in AIDS, 211–212
- Sulfitting agents, and anaphylaxis, 846
- Sulfonamides, allergic reactions to, 867–868
- Sun exposure, in pregnant traveler, 1318
- Surgical treatment, patient selection for, 1185–1250
- Sweating, with acute anemia, 728
- Swellings, subcutaneous, in returning travelers, 1404, 1406–1408
- Swimmer's itch, in returning travelers, 1408
- Swimming pool granuloma, in returning travelers, 1399
- Sympathetic nervous system, in advanced heart failure, 1064
- Syphilis, in travelers, 1452–1453  
of neurologic system, in late HIV infection, 76
- Systemic disease, as contraindication to lung transplantation, 1211–1212  
in chronic urticaria, 816
- Systolic function, changes in, in advanced heart failure, 1062
- T lymphocyte(s), in allergic disease, sources of, 780  
subset analysis of, of HIV infection, 11–12
- Tachycardia, in anaphylaxis, 847, 849  
in high altitude travelers, 1482  
with acute anemia, 728
- Taenia* species, intestinal infection with, in returned travelers, 1445
- Tapeworm, in immigrants, 1470  
in returned travelers, 1445
- Television programs, for smoking cessation, 465–466
- Temperature, characteristics of, in fever, in returned traveler, 1383–1385  
effect in sickle cell disease, 670
- Terfenadine, for urticaria/angioedema, 824–825
- Tetanus vaccine, for international travelers, 1289–1290
- Thalassemia(s), and hemolytic anemia, 663–665  
and ineffective erythropoiesis, in elderly, 628  
and microcytic anemia, 563–564  
interaction with sickling, 670
- Thalassemia traits, in pregnancy, 643–644
- Theophylline, for asthma, 958
- Thromboembolism, with total hip replacement, 1240
- Thrombolysis, adjunctive, for coronary revascularization, 1100–1101  
effects of smoking on, 342  
for chronic extremity ischemia, 1114–1116
- Thrombosis, with intracoronary angiography, 1109  
with total knee replacement, 1245

- Thrombotic thrombocytopenic purpura, and hemolytic anemia, 656-657
- Thromboxane A<sub>2</sub>, biologic effects of, 808
- Thrombus formation, smoking and, 340
- Thrush, in HIV infection, 181
- Thyroid status, in macrocytosis, 587
- Tibioperoneal disease, angioplasty for, 1113-1114
- Tick eschar, in returning travelers, 1399-1401
- Tickborne encephalitis vaccine, for international travelers, 1280, 1286
- Tinea versicolor, in returning travelers, 1404-1405
- Tissue plasminogen activator, for chronic extremity ischemia, 1115
- Tobacco, addiction to, motivational model of, 426  
pharmacotherapy of, 431-433  
advertising and promotion of, 521-522  
and health, school curricula about, 520-521  
carcinogenic effects of, synergism with other factors, 310  
children's access to, control of, public policy on, 529-530  
control of, public policy on, advocacy groups focusing on, 536  
approaches to, 518  
future challenges for, 531-532  
overview of, 517-532  
government regulation of, 530  
product liability suits involving, 392, 530-531  
smokeless, use of, trends in, 298-299  
tumorigenic substances in, 309  
use of, and insurance premium differentials, 525  
direct restraints on, public policy on, 518  
economic factors in, public policy on, 518, 523-526  
excise taxes on, 523-525  
in United States, epidemiology of, 289-303  
history of, 289-290  
warning labels on, 519-520
- Tobacco crops, price support programs for, public policy on, 526
- Tobacco-related disease, control of, physician's role in, 532-536  
community advocacy, 535-536  
hospital smoking policy, 533-535  
patient counseling, 533  
professional organization policy, 535  
public policy on, 515-539
- Tobacco smoke, constituents of, and mechanisms of carcinogenesis, 308-311
- environmental, 348, 377-398  
acute irritating effects of, 379  
and cardiopulmonary disease, 384-386  
and children, 379-381  
and lung cancer in adults, 381-384  
components of, 377-379  
legal issues and, 386-393  
judicial action, 389-392  
legislation and regulation, 386-389  
medical issues and, 377-386
- Occupational Safety and Health Administration report on, 529
- tumorigenic substances in, 309
- Tolerance, in nicotine addiction, definition of, 429
- Toluene diisocyanate bronchial challenge test, for occupational asthma, 923
- Total joint replacement, contraindications to, 1237  
indications for, 1235-1236  
of hip, 1235-1243  
of knee, 1243-1246  
patient education in, 1236-1237  
postoperative rehabilitation with, 1238-1239  
preoperative evaluation for, 1237-1238
- Toxoplasmosis, following heart transplantation, 1130-1133  
in AIDS, 205-216  
clinical manifestations of, 207-209  
diagnosis of, 209-211  
histopathology of, 207  
pathology and pathogenesis of, 206-207  
prophylaxis for, 215  
retinal, 91  
spiramycin for, 213  
treatment of, 211-215  
in HIV infection, 23
- Tranexameric acid, for hereditary angioedema, 833
- Transdermal nicotine, for tobacco addiction treatment, 431, 457-458, 486-487, 507
- Transferrin, in iron transport, 552  
saturation of, during pregnancy, 637  
in iron deficiency anemia, 558  
serum, during pregnancy, 637  
receptors of, in iron deficiency anemia, 558-559
- Transfusions. See *Blood transfusions; Red blood cells, transfusion of.*
- Transgenic technology, medical applications of, 1029
- Transient ischemic attacks, in chronic anemia, blood transfusion for, 730  
patient history of, and high altitude travel, 1492
- Travel, accidents during, 1264

- ailments related to, 1268–1273  
 cardiac disease and, 1299  
 general medical advice for, 1261–1276  
 medical kit for, 1261–1276  
**Traveler(s)**, diarrhea in, 1357–1373. See also *Travelers' diarrhea*.  
 eosinophilia in, 1413–1432. See also *Eosinophilia*.  
 general advice for, 1261–1276  
 high altitude, 1481–1497  
     acclimatization of, 1482–1484  
     exposure of, 1481–1482  
     pharmacologic advice for, 1490  
     with chronic diseases, 1490–1494  
 international, immunizations for, 1277–1294. See also *Immunizations(s)*.  
**pregnant**, 1313–1326. See also *Pregnant traveler*.  
 returned, diarrhea in, 1368  
     fever in, 1375–1392. See also *Fever*.  
     intestinal parasites in, 1433–1448. See also *Parasites*.  
     skin problems in, 1393–1411  
     sexually transmitted diseases and, 1449–1461. See also *Sexually transmitted diseases*.  
     special health considerations for, 1295–1312  
     written instructions for, 1263  
**Travelers' diarrhea**, 1357–1373  
 bacterial resistance and, 1364  
 clinical characteristics of, 1362  
 dietary considerations in, 1358  
 epidemiology of, 1357–1358  
 etiology of, 1358–1362  
 in children, during international travel, 1309–1310  
 in pregnancy, 1316–1317  
 parasites and, 1361–1362  
 prophylaxis for, 1363–1365  
 susceptibility to, 1358  
 treatment of, 1365–1368  
 vaccines for, 1365  
 viral agents and, 1361  
**Trematode infections**, intestinal, in returned travelers, 1445  
**Triamcinolone**, structural formula for, 961  
**Trichinosis**, and eosinophilia, in travelers, 1420  
     in immigrants, 1468  
**Trichuris trichiura**, intestinal infection with, in returned travelers, 1444  
**Trimethoprim**, for travelers' diarrhea prophylaxis, 1363–1364  
**Trimethoprim-sulfamethoxazole**, for pneumocystosis, 112–115  
     prophylaxis with, 114–115  
     for travelers' diarrhea, 1367  
     prophylaxis with, 1363–1364  
**Trimetrexate**, for pneumocystosis, 112–114  
     for toxoplasmosis, in AIDS, 214  
**Troleandomycin**, for asthma, 964–966  
**Tropical dermatology**, differential diagnosis in, 1410  
**Tropical diseases**, in immigrants, 1463–1480. See also under name of specific disease.  
**Tropical sprue**, in returning expatriots, 1470  
**Trypanosomiasis**, in immigrants, 1467  
     in returning travelers, 1396–1397, 1407  
**Tuberculin skin testing**, in HIV infection, 143–144  
**Tuberculosis**, and fever, in returned traveler, 1378  
     HIV serologic testing in, value of, 142  
     in AIDS, prevalence of, 126  
     in Dade County, Florida, 124–125  
     in developing countries, prevalence of, 127  
     in Hispanics and blacks, 124  
     in HIV infection, 21, 121–147  
         bacille Calmette-Guerin vaccination in, 146  
         bacteriology of, 134–136  
         clinical features of, 127–132  
         culture for, 35  
         diagnosis of, 132–139  
             delayed or missed, reasons for, 137–139  
         drug resistance of, 141–142  
         environmental control of, 145–146  
         epidemiology of, 123–127  
         extrapulmonary, 131–132  
             diagnosis of, 133–134  
         future prospects in, 146–147  
         long-term outcome in, 142–143  
         pathogenesis of, 122–123  
         pathology of, 136–137  
         prevention of, 143–146  
         prophylaxis against, 37–38  
         spectrum of, 132  
         treatment of, 140–143  
     in immigrants, 1465–1466, 1471  
     in internationally adopted children, 1476  
     observed vs expected, in 1980s, 123  
     prevalence of, 122  
     pulmonary, fever pattern in, 1384  
         in HIV infection, 129–131  
             diagnosis of, 133  
         vaccine for, for HIV infection, 146  
             for international travelers, 1280, 1287  
**Tularemia**, in returning travelers, 1397  
**Tumor necrosis factor(s)**, and inflammation, 777  
**erythropoiesis inhibition by**, 750–751

- Tumor necrosis factor(s) (*Continued*)  
     in mycobacterial disease, in HIV infection, 157
- Tungiasis, in returning travelers, 1406-1407
- Typhoid fever, fever pattern in, 1384  
     in returned traveler, 1378  
     vaccine for, for international travelers, 1280, 1287-1288
- Typhus, in immigrants, 1467  
     in returning travelers, 1397
- Ultrasound, for coronary revascularization imaging, 1105-1108
- Universal precautions, against HIV infection, 273-274
- Uremia, anemia with, 712
- Urethritis, chlamydial, in travelers, 1451-1452
- Urinary tract, disease of, in immigrants, 1472  
     infections of, with pancreas transplantation, 1230
- Urokinase, for chronic extremity ischemia, 1114-1116  
     for coronary revascularization, 1100-1101
- Ursodiol, for gallstone therapy, 1145-1146
- Urticaria, 805-840  
     acute, 807-812  
         pathophysiology of, 808-809  
         patient evaluation in, 809-811  
         treatment of, 811-812  
     aquagenic, 823  
     cholinergic, 819-820  
     chronic, medications for, 826  
         pathophysiology of, 813-815  
         patient evaluation in, 815-817  
         treatment of, 817-818  
     cold, 821-822  
     heat, localized, 820  
     pathogenesis of, 806-826  
     physical, diagnostic tests for, 820  
         mast cell degranulation in, 821  
         syndromes of, 819-823  
     potential causes of, 810  
     pressure, delayed, 822  
     solar, 822-823  
     vibratory, 823  
         with vasculitis, 818-819
- Urticaria pigmentosa, 816
- Uterine cancer, mortality rates for, 307
- Vaccines. See also *Immunization(s)*.  
     for travelers' diarrhea, 1365
- Vacuum cleaning, for indoor allergen control, 947
- Variceal hemorrhage, recurrent, liver transplantation for, 1220
- Varicella zoster virus, and retinal necrosis, in AIDS, 90-91
- Vascular disease, peripheral, examination for, 1161-1162  
     history in, 1159-1161  
     vascular laboratory studies of, 1162-1163
- Vascular endothelium, in sickle cell disease, 670
- Vascular permeability, increased, in anaphylaxis, 849
- Vasculitis, urticarial, 818-819
- Vasectomized men, protamine allergy in, 874
- Vasoconstriction, smoking and, 338-339
- Vasodilation, in anaphylaxis, 849  
     with allergen challenge, 771
- Vasodilators, for advanced heart failure, 1074-1076
- Vaso-occlusive events, in sickle cell disease, 672-673
- Vasovagal reaction, anaphylaxis vs, 850
- Vegetable gums, and occupational asthma, 927
- Venom immunotherapy, for insect sting allergy, 888-891  
     dosing schedule for, 890  
     duration of, 890-891  
     indications for, 889  
     patient selection for, 888-889  
     reactions to, 890  
     venom selection for, 889-890
- Venomous insect bite, during travel, management of, 1270
- Venous diseases, surgery for, indications for, 1166-1167
- Ventilator dependency, as contraindication to lung transplantation, 1213
- Ventricular dysfunction, in advanced heart failure, 1060
- Vertebrobasilar artery, angioplasty of, 1116-1117
- Vessel walls, abnormalities of, and hemolysis, 657
- Viral diseases, and travelers' diarrhea, 1361  
     in immigrants, 1468
- Viral infection(s), and diarrhea, in AIDS, 57  
     following heart transplantation, 1131
- Visceral disease, vascular, surgery for, indications for, 1165
- Vitamin B<sub>12</sub>, deficiency of, in elderly, 627-628  
     serum level of, determination of, 592  
         in cobalamin deficiency, 590

- in macrocytosis, 587  
Vitamin deficiencies, and decreased red blood cell production, in HIV infection, 704–705  
Vitiligo, in returning travelers, 1405
- Walking, limitation of, as indication for total joint replacement, 1236  
Water purification, during travel, 1272  
Waterborne infections, during travel, management of, 1272–1273  
Weight gain, smoking cessation and, 411 management of, 490  
Weight loss, in cryptosporidiosis, in AIDS, 217  
in *Mycobacterium avium-intracellulare* complex disease, in HIV infection, 151
- Western blot testing, for HIV infection, 8  
Wheezing, pathogenic bacteria and, 897  
Whipworm, in immigrants, 1469–1470  
Wood dusts, and occupational asthma, 928, 930
- Yellow fever, in returning travelers, 1397  
vaccine for, for international travelers, 1279–1281
- Zidovudine, for AIDS dementia complex, 70  
for HIV infection, 13–14  
adverse effects of, 14  
for prophylaxis, 36–37  
resistance to, 14–15